Repligen (RGEN) 10-Q/A 18 Nov 24 2023 Q3 Quarterly report (amended) Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2023	Oct. 27, 2023
Cover [Abstract]
Amendment Flag	true
Document Type	10-Q/A
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Central Index Key	0000730272
Current Fiscal Year End Date	--12-31
Document Period End Date	Sep. 30, 2023
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Securities Act File Number	000-14656
Entity Registrant Name	REPLIGEN CORP
Entity Filer Category	Large Accelerated Filer
Trading Symbol	RGEN
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2729386
Entity Address, Address Line One	41 Seyon Street, Bldg. 1, Suite 100
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02453
City Area Code	781
Entity Shell Company	false
Smaller reporting company	false
Emerging growth company	false
Local Phone Number	250-0111
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		55,832,013
Amendment Description	Repligen Corporation (“we,” “us,” “our,” or the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (the “Amendment”) to amend and restate certain items in our Quarterly Report on Form 10-Q as of and for the three and nine month periods ended September 30, 2023, originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 31, 2023 (the “Original Report”), as listed in “Items Amended in this Filing” below. In filing this Amendment, we are restating our previously issued unaudited condensed consolidated financial statements as of and for the three and nine months ended September 30, 2023 to correct the misapplication of accounting principles under U.S. GAAP related to the timing of revenue recognition arising from a specific COVID-related cancellation payment, received in connection with a contract modification (collectively, the "Misstatement"), as further described in Note 1 to the unaudited condensed consolidated financial statements herein. This restatement changes the timing of recognition of revenue, including the revenue reported in the Original Report, but will not change the total revenue to be recognized for this payment, nor have any impact on the Company’s previously reported cash and cash equivalent balances. This misapplication did not result from any override of controls, misconduct, or fraud of any kind. In connection with the restatement, the Company determined that it was appropriate to revise the condensed consolidated balance sheet as of December 31, 2022 and the condensed consolidated statement of cash flows for the nine month period ended September 30, 2022, as well as impacted footnote disclosures, in this Form 10-Q/A to correct other unrelated immaterial errors. In addition, we have filed amendments to our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2023, originally filed with the SEC on May 2, 2023, and June 30, 2023, originally filed with the SEC on August 2, 2023, and we are filing an amendment to our Annual Report on Form 10-K for the year ended December 31, 2023, originally filed with SEC on February 22, 2024, and amendments to our Quarterly Reports on Form 10-Q for quarterly periods ended March 31, 2024, originally filed with the SEC on May 1, 2024; and June 30, 2024, originally filed with the SEC on July 30, 2024. In correcting the Misstatement in this Amendment, we have also restated other financial statement line item amounts including but not limited to product revenues, income tax provision, net income, foreign currency translation, deferred revenues, prepaid expenses, deferred taxes and earnings-per-share.

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 630,779		$ 523,458
Marketable securities held to maturity	0		100,299
Accounts receivable, net of reserves of $1,803 and $1,365 at September 30, 2023 and December 31, 2022, respectively	106,158		116,247
Inventories, net	211,372		238,277
Prepaid expenses and other current assets	32,163		19,837
Total current assets	980,472		998,118
Property, plant and equipment, net	201,618		190,673
Intangible assets, net	350,318		360,618
Goodwill	869,252		855,513
Deferred tax assets	1,546		840
Operating lease right of use assets	118,084		125,023
Other noncurrent assets	1,444		815
Total noncurrent assets	1,542,262		1,533,482
Total assets	2,522,734		2,531,600
Current liabilities:
Accounts payable	18,961		27,554
Operating lease liability	3,315		6,957
Current contingent consideration	12,589		13,950
Accrued liabilities	58,118		71,120
Convertible Senior Notes, net	285,956		284,615
Total current liabilities	378,939		404,196
Deferred tax liabilities	14,524		23,000
Noncurrent operating lease liability	130,615		131,389
Noncurrent contingent consideration	13,759		51,559
Other noncurrent liabilities	11,154		10,756
Total noncurrent liabilities	170,052		216,704
Total liabilities	548,991		620,900
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding	0		0
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,774,706 shares at September 30, 2023 and 55,557,698 shares at December 31, 2022 issued and outstanding	558		556
Additional paid-in capital	1,567,233		1,547,266
Accumulated other comprehensive loss	(43,366)		(34,394)
Accumulated earnings	449,318		397,272
Total stockholders' equity	1,973,743	$ 1,956,859	1,910,700	$ 1,835,109	$ 1,805,364	$ 1,750,067
Total liabilities and stockholders' equity	$ 2,522,734		$ 2,531,600

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Accounts receivable, reserve for doubtful accounts	$ 1,803	$ 1,365
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	55,774,706	55,557,698
Common stock, shares outstanding	55,774,706	55,557,698

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue:
Revenue	$ 141,192	$ 200,741	$ 465,741	$ 614,774
Costs and operating expenses:
Cost of product revenue	104,634	86,514	265,786	255,130
Research and development	10,577	10,228	32,437	32,823
Selling, general and administrative	55,582	53,643	160,954	162,592
Contingent consideration	(34,292)	(2,309)	(31,266)	(11,604)
Total costs and operating expenses	136,501	148,076	427,911	438,941
Income from operations	4,691	52,665	37,830	175,833
Other income (expenses):
Investment income	6,662	2,177	18,112	2,962
Interest expense	(408)	(329)	(1,227)	(892)
Amortization of debt issuance costs	(459)	(455)	(1,373)	(1,360)
Other income (expenses)	895	(6,591)	1,500	(10,389)
Other income (expenses), net	6,690	(5,198)	17,012	(9,679)
Income before income taxes	11,381	47,467	54,842	166,154
Income tax (benefit) provision	(5,542)	7,062	2,796	28,924
Net income	$ 16,923	$ 40,405	$ 52,046	$ 137,230
Earnings per share:
Basic	$ 0.3	$ 0.73	$ 0.93	$ 2.48
Diluted (Note 13)	$ 0.3	$ 0.71	$ 0.91	$ 2.39
Weighted average common shares outstanding:
Basic	55,766	55,498	55,688	55,432
Diluted (Note 13)	56,940	57,304	56,933	57,598
Net Income (Loss)	$ 16,923	$ 40,405	$ 52,046	$ 137,230
Other comprehensive income (loss):
Foreign currency translation adjustment	(5,880)	(18,170)	(8,972)	(38,375)
Comprehensive income	11,043	22,235	43,074	98,855
Products
Revenue:
Revenue	141,156	200,708	465,630	614,668
Royalty and other revenue
Revenue:
Revenue	$ 36	$ 33	$ 111	$ 106

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Retained Earnings
Balance at Dec. 31, 2021	$ 1,750,067,000	$ 553,000	$ 1,572,340,000	$ (16,886,000)	$ 194,060,000
Beginning Balance (in shares) at Dec. 31, 2021		55,321,457
Net income	137,230,000				137,230,000
Issuance of common stock for debt conversion	(5,000)	$ 0	(5,000)
Issuance of common stock for debt conversion (in shares)		15
Exercise of stock options and vesting of stock units	2,784,000	$ 3,000	2,781,000
Exercise of stock options and vesting of stock units (in shares)		281,839
Tax withholding on vesting of restricted stock units	(15,829,000)	$ (1,000)	(15,828,000)
Tax withholding on vesting of restricted stock units (in shares)		(83,665)
Stock-based compensation expense	21,054,000		21,054,000
Translation adjustment	(38,375,000)			(38,375,000)
Balance at Sep. 30, 2022	1,835,109,000	$ 555,000	1,541,272,000	(55,261,000)	348,543,000
Balance (Accounting Standards Update 2020-06 [Member]) at Sep. 30, 2022	(21,817,000)		(39,070,000)		17,253,000
Ending Balance (in shares) at Sep. 30, 2022		55,519,646
Balance at Jun. 30, 2022	1,805,364,000	$ 555,000	1,533,762,000	(37,091,000)	308,138,000
Beginning Balance (in shares) at Jun. 30, 2022		55,465,918
Net income	40,405,000				40,405,000
Issuance of common stock for debt conversion	0	$ 0	0
Issuance of common stock for debt conversion (in shares)		3
Exercise of stock options and vesting of stock units	2,321,000	$ 0	2,321,000
Exercise of stock options and vesting of stock units (in shares)		59,112
Tax withholding on vesting of restricted stock units	(1,070,000)	$ 0	(1,070,000)
Tax withholding on vesting of restricted stock units (in shares)		(5,387)
Stock-based compensation expense	6,154,000		6,154,000
Translation adjustment	(18,170,000)			(18,170,000)
Other	105,000		105,000
Balance at Sep. 30, 2022	1,835,109,000	$ 555,000	1,541,272,000	(55,261,000)	348,543,000
Balance (Accounting Standards Update 2020-06 [Member]) at Sep. 30, 2022	(21,817,000)		(39,070,000)		17,253,000
Ending Balance (in shares) at Sep. 30, 2022		55,519,646
Balance at Dec. 31, 2022	1,910,700,000	$ 556,000	1,547,266,000	(34,394,000)	397,272,000
Beginning Balance (in shares) at Dec. 31, 2022		55,557,698
Net income	52,046,000				52,046,000
Issuance of common stock for debt conversion	(13,000)		(13,000)
Issuance of common stock for debt conversion (in shares)		8
Exercise of stock options and vesting of stock units	356,000	$ 3,000	353,000
Exercise of stock options and vesting of stock units (in shares)		212,589
Tax withholding on vesting of restricted stock units	(12,178,000)	$ (1,000)	(12,177,000)
Tax withholding on vesting of restricted stock units (in shares)		(69,625)
Issuance of commons stock pursuant to the acquisition	5,465,000		5,465,000
Issuance of commons stock pursuant to the acquisition, (in shares)		31,415
Issuance of common stock pursuant to the acquisition of FlexBiosys, Inc.	7,229,000		7,229,000
Issuance of common stock pursuant to the Avitide, Inc.contingent consideration earnout payment		$ 42,621
Stock-based compensation expense	19,110,000		19,110,000
Translation adjustment	(8,972,000)			(8,972,000)
Balance at Sep. 30, 2023	1,973,743,000	$ 558,000	1,567,233,000	(43,366,000)	449,318,000
Ending Balance (in shares) at Sep. 30, 2023		55,774,706
Balance at Jun. 30, 2023	1,956,859,000	$ 557,000	1,561,393,000	(37,486,000)	432,395,000
Beginning Balance (in shares) at Jun. 30, 2023		55,744,896
Net income	16,923,000				16,923,000
Issuance of common stock for debt conversion	(10,000)		(10,000)
Issuance of common stock for debt conversion (in shares)		2
Exercise of stock options and vesting of stock units	294,000	$ 1,000	293,000
Exercise of stock options and vesting of stock units (in shares)		36,195
Tax withholding on vesting of restricted stock units	(1,038,000)		(1,038,000)
Tax withholding on vesting of restricted stock units (in shares)		(6,387)
Issuance of commons stock pursuant to the acquisition	222,000		222,000
Stock-based compensation expense	6,373,000		6,373,000
Translation adjustment	(5,880,000)			(5,880,000)
Balance at Sep. 30, 2023	$ 1,973,743,000	$ 558,000	$ 1,567,233,000	$ (43,366,000)	$ 449,318,000
Ending Balance (in shares) at Sep. 30, 2023		55,774,706

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net income	$ 52,046	$ 137,230
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	51,295	36,605
Amortization of debt issuance costs	1,373	1,360
Stock-based compensation	19,110	21,054
Deferred income taxes, net	(9,268)	1,722
Contingent consideration	(31,266)	(11,604)
Non-cash interest income	(2,023)	0
Operating lease right of use asset amortization*	10,203	5,672
Other	1,275	210
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable	8,315	(8,609)
Inventories	25,979	(64,308)
Prepaid expenses and other assets	(12,749)	168
Other assets	(707)	(298)
Accounts payable	(8,619)	(10,124)
Accrued expenses	(12,514)	3,043
Operating lease Liabilities	(7,676)	(1,548)
Long-term liabilities	79	(372)
Total cash provided by operating activities	84,853	110,201
Cash flows from investing activities:
Acquisitions, net of cash acquired	(27,843)	0
Proceeds from maturity of marketable securities held to maturity	102,323	0
Additions to capitalized software costs	(2,736)	(2,568)
Purchases of property, plant and equipment	(25,135)	(64,390)
Purchase of intellectual property	0	(45,000)
Other investing activities	21	30
Total cash provided by (used in) investing activities	46,630	(111,928)
Cash flows from financing activities:
Proceeds from exercise of stock options	356	2,784
Payment of tax withholding obligation on vesting of restricted stock	(12,178)	(15,829)
Repayment of Convertible Senior Notes	(33)	(18)
Payment of earnout consideration	(7,298)	0
Proceeds from issuance of common stock, net	(13)	0
Total cash used in financing activities	(19,166)	(13,063)
Effect of exchange rate changes on cash and cash equivalents	(4,996)	(15,661)
Net increase (decrease) in cash and cash equivalents	107,321	(30,451)
Cash, cash equivalents and restricted cash, beginning of period	523,458	603,814
Cash and cash equivalents, end of period	630,779	573,363
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases	1,129	25,705
FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 31,415 shares of common stock issued for the acquisition of FlexBiosys, Inc.	5,465	0
Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of contingent consideration earnouts related to acquisition	$ 7,229	$ 0

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - shares		9 Months Ended
	Apr. 17, 2023	Sep. 30, 2023
FlexBiosys, Inc.
Shares of common stock issued for acquisition	31,415	31,415
Avitide, Inc.
Shares of common stock issued for acquisition		42,621

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 16,923	$ 40,405	$ 52,046	$ 137,230

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Restatement of Previously Issue

Restatement of Previously Issued Financial Statements	9 Months Ended
	Sep. 30, 2023
Accounting Changes and Error Corrections [Abstract]
Restatement of Previously Issued Financial Statements	1. Restatement of Previously Issued Financial Statements Subsequent to the issuance of the Original Report on October 31, 2023, the Company identified a material accounting error related to the timing of revenue recognition which impacts the Company’s condensed consolidated financial statements as of and for the three and nine month periods ended September 30, 2023 ("the Misstatement"). Within this report, the Company has restated all impacted financial information and footnote disclosures impacted by the Misstatement. A description of the error and its impact on the previously issued financial statements is included below. In connection with the restatement, the Company determined that it was appropriate to revise the condensed consolidated balance sheet as of December 31, 2022 and the condensed consolidated statement of cash flows for the nine month period ended September 30, 2022, as well as impacted footnote disclosures, in this Form 10-Q/A to correct other unrelated immaterial errors. Description of revenue restatement adjustments During the first quarter of 2023, a customer cancelled two COVID-related, non-cancellable product purchase orders (“Cancelled PO’s”) in exchange for a $ 17.3 million one-time cash payment (the “Payment”), which was received in April 2023. At the time of cancellation, no product units had been delivered under the Cancelled PO’s and the Company had two other purchase orders from the same customer for the same product (“Open PO’s”). The Company originally accounted for the Cancelled PO’s as a single contract and recognized the $ 17.3 million payment as component of product revenue in the first quarter of 2023. Subsequent to the issuance of the Original Report, the Company reassessed the accounting treatment of the Payment and concluded that the Cancelled PO’s and Open PO’s represented a combined contract such that the February 2023 transaction should have been analyzed and accounted for as a contract modification, which required the Payment to be deferred and recognized as product units were delivered under the Open PO’s. All Open PO product units were fully delivered to the customer by June 30, 2024. The correction of the Misstatement affects certain financial statement line items in these condensed consolidated financial statements including but not limited to product revenues, income tax provision, foreign currency translation, deferred revenues, prepaid expenses, deferred taxes and earnings-per-share. Consolidated Financial Statements - Restatement Reconciliation Tables The following tables present the impact of the financial statement adjustments on the Company's previously reported condensed consolidated financial statements. The "Previously Reported" amounts in the following tables are amounts derived from the Original Report. The amounts in the columns labeled "Revenue Adjustments" represent the effect of adjustments resulting from the correction of the overstatement of revenues associated with the Payment and related tax impact. The amounts in the columns labeled "Other Adjustments" represent the effect of other adjustments that relate to other unrelated errors in previously filed financial statements that were not material, individually or in the aggregate, to those filed financial statements. The effects of both the restatement for the Revenue Adjustments and the immaterial Other Adjustments have been corrected in all impacted tables and footnotes throughout these condensed consolidated financial statements. September 30, 2023 As Previously Reported Revenue Adjustments Other Adjustments As Restated ASSETS Current assets: Cash and cash equivalents $ 630,779 $ — $ — $ 630,779 Marketable securities held to maturity — — — — Accounts receivable, net of reserves of $ 1,803 and $ 1,365 at 106,158 — — 106,158 Inventories, net 211,372 — — 211,372 Prepaid expenses and other current assets 30,147 2,016 — 32,163 Total current assets 978,456 2,016 — 980,472 Noncurrent assets: Property, plant and equipment, net 201,618 — — 201,618 Intangible assets, net 343,729 — 6,589 350,318 Goodwill 869,252 — — 869,252 Deferred tax assets 1,546 — — 1,546 Operating lease right of use assets 118,084 — — 118,084 Other noncurrent assets 1,444 — — 1,444 Total noncurrent assets 1,535,673 — 6,589 1,542,262 Total assets $ 2,514,129 $ 2,016 $ 6,589 $ 2,522,734 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 18,961 $ — $ — $ 18,961 Operating lease liability 3,315 — — 3,315 Current contingent consideration 12,589 — — 12,589 Accrued liabilities 42,543 15,575 — 58,118 Convertible Senior Notes, net 285,956 — — 285,956 Total current liabilities 363,364 15,575 — 378,939 Noncurrent liabilities: — Deferred tax liabilities 14,036 667 ( 179 ) 14,524 Noncurrent operating lease liability 130,615 — — 130,615 Noncurrent contingent consideration 13,759 — — 13,759 Other noncurrent liabilities 3,798 — 7,356 11,154 Total noncurrent liabilities 162,208 667 7,177 170,052 Total liabilities 525,572 16,242 7,177 548,991 Commitments and contingencies (Note 11) Stockholders' equity: Preferred stock, $ 0.01 par value, 5,000,000 shares authorized, no shares — — — — Common stock, $ 0.01 par value; 80,000,000 shares authorized; 55,774,706 55,557,698 shares at December 31, 2022 558 — — 558 Additional paid-in capital 1,567,233 — — 1,567,233 Accumulated other comprehensive loss ( 43,571 ) 205 — ( 43,366 ) Accumulated earnings 464,337 ( 14,431 ) ( 588 ) 449,318 Total stockholders’ equity 1,988,557 ( 14,226 ) ( 588 ) 1,973,743 Total liabilities and stockholders’ equity $ 2,514,129 $ 2,016 $ 6,589 $ 2,522,734 December 31, 2022 As Previously Reported Other Adjustments As Revised ASSETS Intangible assets, net $ 353,676 $ 6,942 $ 360,618 Total noncurrent assets 1,526,540 6,942 1,533,482 Total assets $ 2,524,658 $ 6,942 $ 2,531,600 LIABILITIES AND STOCKHOLDERS' EQUITY Other noncurrent liabilities $ 3,814 $ 6,942 $ 10,756 Total noncurrent liabilities 209,762 6,942 216,704 Total liabilities 613,958 6,942 620,900 Total liabilities and stockholders’ equity $ 2,524,658 $ 6,942 $ 2,531,600 Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 As Previously Reported Revenue Adjustments Other Adjustments As Restated As Previously Reported Revenue Adjustments Other Adjustments As Restated Revenue: Products $ 141,156 $ — $ — $ 141,156 $ 482,910 $ ( 17,280 ) $ — $ 465,630 Royalty and other revenue 36 — — 36 111 — — 111 Total revenue 141,192 — — 141,192 483,021 ( 17,280 ) — 465,741 Costs and operating expenses: Cost of product revenue 104,634 — — 104,634 265,786 — — 265,786 Research and development 10,577 — — 10,577 32,437 — — 32,437 Selling, general and administrative 55,465 — 117 55,582 160,601 — 353 160,954 Contingent consideration ( 34,292 ) — — ( 34,292 ) ( 31,266 ) — — ( 31,266 ) Total costs and operating expenses 136,384 — 117 136,501 427,558 — 353 427,911 Income from operations 4,808 — ( 117 ) 4,691 55,463 ( 17,280 ) ( 353 ) 37,830 Other income (expenses): Investment income 6,662 — — 6,662 18,112 — — 18,112 Interest expense ( 269 ) — ( 139 ) ( 408 ) ( 813 ) — ( 414 ) ( 1,227 ) Amortization of debt issuance costs ( 459 ) — — ( 459 ) ( 1,373 ) — — ( 1,373 ) Other income (expenses) 895 — — 895 1,500 — — 1,500 Other income (expenses), net 6,829 — ( 139 ) 6,690 17,426 — ( 414 ) 17,012 Income before income taxes 11,637 — ( 256 ) 11,381 72,889 ( 17,280 ) ( 767 ) 54,842 Income tax (benefit) provision ( 6,535 ) 1,053 ( 60 ) ( 5,542 ) 5,824 ( 2,849 ) ( 179 ) 2,796 Net income $ 18,172 $ ( 1,053 ) $ ( 196 ) $ 16,923 $ 67,065 $ ( 14,431 ) $ ( 588 ) $ 52,046 Earnings per share: Basic $ 0.33 $ ( 0.02 ) $ ( 0.01 ) $ 0.30 $ 1.20 $ ( 0.26 ) $ ( 0.01 ) $ 0.93 Diluted (Note 13) $ 0.32 $ ( 0.02 ) $ — $ 0.30 $ 1.18 $ ( 0.25 ) $ ( 0.02 ) $ 0.91 Weighted average common shares outstanding: Basic 55,766 — — 55,766 55,688 — — 55,688 Diluted (Note 13) 56,940 — — 56,940 56,933 — — 56,933 Net income $ 18,172 $ ( 1,053 ) $ ( 196 ) $ 16,923 $ 67,065 $ ( 14,431 ) $ ( 588 ) $ 52,046 Other comprehensive income (loss): Foreign currency translation adjustment ( 6,382 ) 502 — ( 5,880 ) ( 9,177 ) 205 — ( 8,972 ) Comprehensive income $ 11,790 $ ( 551 ) $ ( 196 ) $ 11,043 $ 57,888 $ ( 14,226 ) $ ( 588 ) $ 43,074 Accumulated Other Comprehensive Loss Accumulated Earnings Total Stockholders' Equity As Previously Reported Revenue Adjustments Other Adjustments As Restated As Previously Reported Revenue Adjustments Other Adjustments As Restated As Previously Reported Revenue Adjustments Other Adjustments As Restated $ $ $ $ $ $ $ $ $ $ $ $ Balance at June 30, 2023 ( 37,189 ) ( 297 ) — ( 37,486 ) 446,165 ( 13,378 ) ( 392 ) 432,395 1,970,926 ( 13,675 ) ( 392 ) 1,956,859 Net income — — — — 18,172 ( 1,053 ) ( 196 ) 16,923 18,172 ( 1,053 ) ( 196 ) 16,923 Translation adjustment ( 6,382 ) 502 — ( 5,880 ) — — — — ( 6,382 ) 502 — ( 5,880 ) Balance at September 30, 2023 ( 43,571 ) 205 — ( 43,366 ) 464,337 ( 14,431 ) ( 588 ) 449,318 1,988,557 ( 14,226 ) ( 588 ) 1,973,743 Accumulated Other Comprehensive Loss Accumulated Earnings Total Stockholders' Equity As Previously Reported Revenue Adjustments Other Adjustments As Restated As Previously Reported Revenue Adjustments Other Adjustments As Restated As Previously Reported Revenue Adjustments Other Adjustments As Restated $ $ $ $ $ $ $ $ $ $ $ $ Balance at December 31, 2022 ( 34,394 ) — — ( 34,394 ) 397,272 — — 397,272 1,910,700 — — 1,910,700 Net income — — — — 67,065 ( 14,431 ) ( 588 ) 52,046 67,065 ( 14,431 ) ( 588 ) 52,046 Translation adjustment ( 9,177 ) 205 — ( 8,972 ) — — — — ( 9,177 ) 205 — ( 8,972 ) Balance at September 30, 2023 ( 43,571 ) 205 — ( 43,366 ) 464,337 ( 14,431 ) ( 588 ) 449,318 1,988,557 ( 14,226 ) ( 588 ) 1,973,743 Nine Months Ended September 30, 2023 As Previously Reported Revenue Adjustments Other Adjustments As Restated Cash flows from operating activities: Net income $ 67,065 $ ( 14,431 ) $ ( 588 ) $ 52,046 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 50,942 — 353 51,295 Amortization of debt issuance costs 1,373 — — 1,373 Stock-based compensation 19,110 — — 19,110 Deferred income taxes, net ( 9,756 ) 667 ( 179 ) ( 9,268 ) Contingent consideration ( 31,266 ) — — ( 31,266 ) Non-cash interest income ( 2,023 ) — — ( 2,023 ) Operating lease right of use asset amortization 10,203 — — 10,203 Other 861 — 414 1,275 Changes in operating assets and liabilities, excluding impact of acquisitions: Accounts receivable 8,315 — — 8,315 Inventories 25,979 — — 25,979 Prepaid expenses and other assets ( 10,733 ) ( 2,016 ) — ( 12,749 ) Other assets ( 707 ) — — ( 707 ) Accounts payable ( 8,619 ) — — ( 8,619 ) Accrued expenses ( 28,294 ) 15,780 — ( 12,514 ) Operating lease liabilities ( 7,676 ) — — ( 7,676 ) Long-term liabilities 79 — — 79 Total cash provided by operating activities 84,853 — — 84,853 Cash flows from investing activities: Acquisitions, net of cash acquired ( 27,843 ) — — ( 27,843 ) Proceeds from maturity of marketable securities held to maturity 102,323 — — 102,323 Additions to capitalized software costs ( 2,736 ) — — ( 2,736 ) Purchases of property, plant and equipment ( 25,135 ) — — ( 25,135 ) Purchase of intellectual property — — — — Other investing activities 21 — — 21 Total cash provided by (used in) investing activities 46,630 — — 46,630 Cash flows from financing activities: Proceeds from exercise of stock options 356 — — 356 Payment of tax withholding obligation on vesting of restricted stock ( 12,178 ) — — ( 12,178 ) Repayment of Convertible Senior Notes ( 33 ) — — ( 33 ) Payment of earnout consideration ( 7,298 ) — — ( 7,298 ) Proceeds from issuance of common stock, net ( 13 ) — — ( 13 ) Total cash used in financing activities ( 19,166 ) — — ( 19,166 ) Effect of exchange rate changes on cash and cash equivalents ( 4,996 ) — — ( 4,996 ) Net increase (decrease) in cash and cash equivalents 107,321 — — 107,321 Cash, cash equivalents and restricted cash, beginning of period 523,458 — — 523,458 Cash and cash equivalents, end of period $ 630,779 $ — $ — $ 630,779 Supplemental disclosure of non-cash investing and financing activities: Assets acquired under operating leases $ 1,129 $ — $ — $ 1,129 Fair value of 31,415 shares of common stock issued for the acquisition of $ 5,465 $ — $ — $ 5,465 Fair value of 42,621 shares of common stock issued for the Avitide, Inc. $ 7,229 $ — $ — $ 7,229 Nine Months Ended September 30, 2022 As Previously Reported Other Adjustments As Revised Cash flows from operating activities: Adjustments to reconcile net income to net cash provided by operating activities: Operating lease right of use asset amortization $ ( 22,033 ) $ 27,705 $ 5,672 Changes in operating assets and liabilities, excluding impact of acquisitions: Operating lease liabilities $ 26,157 $ ( 27,705 ) $ ( 1,548 ) Total cash provided by operating activities $ 110,201 $ — $ 110,201

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements included herein have been prepared by Repligen Corporation in accordance with generally accepted accounting principles accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and footnote disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on February 22, 2023 (“Form 10-K”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The business and economic uncertainty resulting from government-mandated actions in response to the COVID-19 pandemic, including all subsequent variants of the SARS-CoV-2 coronavirus ("COVID-19"), global geopolitical conflicts, supply chain challenges, cost pressure and the overall effects of the current high inflation environment on customers' purchasing patterns has made such estimates more difficult to calculate. Accordingly, actual results could differ from those estimates. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company made no material changes in the application of its significant accounting policies that were disclosed in its Form 10-K. In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of its financial position as of September 30, 2023, its results of operations for the three and nine months ended September 30, 2023 and 2022 and cash flows for the three and nine months ended September 30, 2023 and 2022. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year. Recent Accounting Standards Updates We consider the applicability and impact of all Accounting Standards Updates ("ASU" or "ASUs") on the Company’s condensed consolidated financial statements. As of September 30, 2023, there were no accounting standards or ASUs recently issued or effective during the fiscal year that would have a material effect on the Company's condensed consolidated financial statements or disclosures.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2023
Disclosure Text Block [Abstract]
Fair Value Measurements	3. Fair Value Measurements The Company uses various valuation approaches in determining the fair value of its assets and liabilities. The Company employs a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access Level 2 - Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement. Cash, Cash Equivalents and Marketable Securities Held to Maturity The following table summarizes the Company's cash, cash equivalents and marketable securities held to maturity as of September 30, 2023 and December 31, 2022 (amounts in thousands): As of September 30, 2023 Amortized Gross Gross Estimated Cash and cash equivalents: Cash and money market funds $ 630,779 $ — $ — $ 630,779 Total cash and cash equivalents $ 630,779 $ — $ — $ 630,779 As of December 31, 2022 Amortized Gross Gross Estimated Cash and cash equivalents: Cash and money market funds $ 523,458 $ — $ — $ 523,458 Total cash and cash equivalents 523,458 — — 523,458 Marketable securities held to maturity: U.S. treasury bills – short-term 100,299 24 — 100,323 Total cash, cash equivalents and marketable securities $ 623,757 $ 24 $ — $ 623,781 During the fourth quarter of 2022, the Company purchased $ 100.0 million of 6-month U.S. treasury bills with the positive intent and ability to hold them until maturity. Therefore, the Company classified this investment as held to maturity and stated it at amortized cost on the condensed consolidated balance sheet. These U.S. treasury bills matured in June 2023. The amortized cost and the fair value of the Company's held to maturity securities by contractual maturity at December 31, 2022 is summarized below: December 31, 2022 Amortized Estimated Maturity of one year or less $ 100,299 $ 100,323 Total $ 100,299 $ 100,323 Fair Value Measured on a Recurring Basis Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of September 30, 2023 and December 31, 2022 (amounts in thousands): As of September 30, 2023 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 389,473 $ — $ — $ 389,473 Liabilities: Short-term contingent consideration $ — $ — $ 12,589 $ 12,589 Long-term contingent consideration $ — $ — $ 13,759 $ 13,759 As of December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 343,929 $ — $ — $ 343,929 Liabilities: Short-term contingent consideration $ — $ — $ 13,950 $ 13,950 Long-term contingent consideration $ — $ — $ 51,559 $ 51,559 Contingent Consideration – Earnouts As of September 30, 2023 , the maximum amount of future contingent consideration (undiscounted) that we could be required to pay in connection with the completed acquisitions of Avitide, Inc. ("Avitide") in September 2021 and FlexBiosys, Inc. ("FlexBiosys") in April 2023, was $ 125.0 million over a three-year earnout period and $ 42.0 million over a two-year earnout period, respectively. Refer to Note 4, "Acquisitions" included in Part II, Item 8, “ Financial Statements and Supplementary Data” to our Form 10-K and Note 4, "Acquisition of FlexBiosys, Inc.," to this report for additional information on the contingent consideration earnouts. During 2023, expected results and a change in market inputs used to calculate the discount rate, resulted in a decrease in amounts reported as of September 30, 2023 . A reconciliation of the change in the fair value of contingent consideration – earnouts is included in the following table (amounts in thousands): Balance at December 31, 2022 $ 65,509 Acquisition date fair value of contingent consideration earnout 6,632 Payment of contingent consideration earnout ( 14,527 ) Decrease in fair value of contingent consideration earnouts ( 31,266 ) Balance at September 30, 2023 $ 26,348 The recurring Level 3 fair value measurement of our contingent consideration earnout that we expect to be required to settle our 2023, 2024 and 2025 contingent consideration obligations for Avitide and FlexBiosys include the following significant unobservable inputs (amounts in thousands, except percent data): Contingent Consideration Earnout Fair Value as of Valuation Technique Unobservable Input Range Weighted Average (1) Probability of Success 100 % 100 % Commercialization-based payments $ 19,383 Monte Carlo Earnout Discount Rate 7.1 % 7.1 % Volatility 13.1 %- 24.6 % 21.7 % Revenue and Volume- $ 1,460 Monte Carlo Revenue & Volume 5.1 %- 9.3 % 8.2 % Earnout Discount Rate 6.1 %- 7.1 % 6.5 % Probability of 100 % 100 % Manufacturing line expansions $ 5,505 Probability-weighted present value Earnout Discount Rate 6.1 %- 6.4 % 6.3 % (1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. Fair Value Measured on a Nonrecurring Basis During the three and nine months ended September 30, 2023 , there were no re-measurements to the fair value of financial assets and liabilities that are measured at fair value on a nonrecurring basis.

Acquisition of FlexBiosys, Inc

Acquisition of FlexBiosys, Inc	9 Months Ended
	Sep. 30, 2023
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Acquisition of FlexBiosys, Inc.	4. Acquisition of FlexBiosys, Inc. On April 17, 2023 , the Company completed its acquisition of all of the outstanding equity interests in FlexBiosys, pursuant to an Equity Purchase Agreement ("EPA") with FlexBiosys, TSAP Holdings Inc. ("NJ Seller"), Gayle Tarry and Stanley Tarry, as individuals (collectively with NJ Seller, the "Sellers"), and Stanley Tarry, in his capacity as the representative of the Sellers (the "FlexBiosys Acquisition"). FlexBiosys, which is headquartered in Branchburg, New Jersey, offers expert design and custom manufacturing of single-use bioprocessing products and a comprehensive range of products that include bioprocessing bags, bottles, and tubing assemblies. These products will complement and expand our fluid management portfolio of offerings. Consideration transferred The FlexBiosys Acquisition was accounted for as a purchase of a business under ASC 805, "Business Combinations," and the Company engaged a third-party valuation firm to assist with the valuation of FlexBiosys. Under the terms of the EPA, all outstanding equity interests of FlexBiosys were acquired for consideration with a value totaling $ 41.0 million. The FlexBiosys Acquisition was funded through payment of $ 29.0 million in cash, which includes $ 6.3 million deposited in escrow for future payments, the issuance of 31,415 unregistered shares of the Company's common stock totaling $ 5.4 million and contingent consideration with fair value of approximately $ 6.6 million. Under the acquisition method of accounting, the assets acquired and liabilities assumed of FlexBiosys were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. The fair value of the net assets acquired is estimated to be $ 14.1 million, the fair value of the intangible assets acquired is estimated to be $ 12.6 million and the residual goodwill is estimated to be $ 14.3 million. The estimated consideration and preliminary purchase price information has been prepared using a preliminary valuation. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company has incurred $ 0.9 million of transaction and integration costs associated with the FlexBiosys Acquisition from the date of acquisition to September 30, 2023 with $ 0.5 million of the transaction and integration costs incurred during the three months ended September 30, 2023. The transaction costs are included in operating expenses in the consolidated statements of comprehensive income for the three and nine months ended September 30, 2023. Fair Value of Net Assets Acquired The preliminary allocation of purchase price is based on the fair value of assets acquired and liabilities assumed as of the acquisition date. As of September 30, 2023, the purchase accounting for this acquisition had not been finalized. As additional information becomes available, the Company may further revise its preliminary purchase price allocation during the remainder of the measurement period. Besides tax implications of the purchase price allocation, the final allocation may result in changes to other assets and liabilities. The components and estimated allocation of the purchase price consist of the following (amounts in thousands): Cash and cash equivalents $ 1,090 Accounts receivable 683 Inventory 667 Prepaid expenses and other current assets 35 Property and equipment 12,034 Operating lease right of use asset 3,537 Customer relationships 2,530 Developed technology 9,860 Trademark and tradename 30 Non-competition agreements 220 Goodwill 14,321 Other long-term assets 10 Accounts payable ( 136 ) Accrued liabilities ( 314 ) Operating lease liability ( 39 ) Operating lease liability, long-term ( 3,498 ) Fair value of net assets acquired $ 41,030 During the third quarter of 2023, the Company recorded an immaterial net working capital adjustment related to the FlexBiosys Acquisition, which is included in goodwill in the table above. Acquired Goodwill The goodwill of $ 14.3 million represents future economic benefits expected to arise from anticipated synergies from the integration of FlexBiosys into the Company. These synergies include operating efficiencies and strategic benefits projected to be achieved as a result of the FlexBiosys Acquisition. Substantially all of the goodwill recorded is expected to be deductible for income tax purposes. Intangible Assets The following table sets forth the components of the identified intangible assets associated with the FlexBiosys Acquisition and their estimated useful lives: Useful life Fair Value (Amounts in thousands) Customer relationships 12 years $ 2,530 Developed technology 16 years 9,860 Trademark and tradename 4 years 30 Non-competition agreements 5 years 220 $ 12,640

Restructuring Plan

Restructuring Plan	9 Months Ended
	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring Plan	5. Restructuring Plan As previously disclosed, in July 2023 the Board of Directors authorized the Company's management team to undertake restructuring activities to simplify and streamline our organization and strengthen the overall effectiveness of our operations (the "Restructuring Plan"). In addition to the initial streamlining and re-balancing efforts contemplated in July, the Company is undertaking further restructuring activities (collectively, the "Restructuring Plan") which include consolidating a portion of our manufacturing operations between certain U.S. locations, discontinuing the sale of certain product SKUs, and evaluating raw materials and components secured during the 2020-2022 COVID-19 pandemic period (the "COVID-19 Period") to meet increasing demand during a challenging supply chain environment in the industry. These activities are expected to be substantially completed by the end of 2023. The Company recorded pre-tax costs of $ 24.0 million for the three and nine months ended September 30, 2023, related to the Restructuring Plan and for the full year of 2023 the Company expects to record charges of approximately $ 26 million, with the remaining costs in the fourth quarter related to remaining severance and employee-related costs. Approximately $ 21 million will be non-cash, relating primarily to an inventory write-off to adjust inventory to net realizable value and accelerated depreciation on equipment related to the shutdown of manufacturing facilities and production lines, the remaining costs will be cash expenses, primarily related to severance and employee-related costs. The Company recorded pre-tax costs of $ 24.0 million for the three and nine months ended September 30, 2023 related to the Restructuring Plan and for the full year of 2023 the Company expects to record charges of approximately $ 26 million. The following table summarizes the charges related to restructuring activities by type of cost: Three and Nine Months Ended September 30, 2023 Severance & Employee-Related Costs Inventory Write-Off Accelerated Depreciation Facility and Other Exit Costs Total (Amounts in thousands) Cost of product revenue $ 1,654 $ 17,185 $ 3,788 $ 84 $ 22,711 Research and development 34 — 1 — 35 Selling, general and administrative 1,142 — 27 97 1,266 $ 2,830 $ 17,185 $ 3,816 $ 181 $ 24,012 Severance and employee-related costs under the Restructuring Plan are associated with actual headcount reductions. Costs incurred include cash severance and non-cash severance, including other termination benefits. Severance and other termination benefit packages are based on established benefit arrangements or local statutory requirements and we recognized the contractual component of these benefits when payment was probable and could be reasonably estimated. The inventory write-off includes the impact of the Company discontinuing the sale of certain product SKUs and the impact of having proactively secured materials during the COVID-19 Period to meet accelerated demand during a challenging supply chain environment in the industry. Where demand has reduced, finished goods and raw materials, whose value exceeded the projected requirements to be used before reaching their expiration date, were written down to their realizable value. The Restructuring Plan also includes the closing of manufacturing facilities and production lines, which included inventory that could not be repurposed. Non-cash charges for accelerated depreciation were recognized on long-lived assets that were taken out of service before the end of their normal service due to the shutdown of manufacturing facilities and production lines, in which case depreciation estimates were revised to reflect the use of the assets over their shortened useful life. The restructuring accrual is included in accrued liabilities in the condensed consolidated balance sheet as of September 30, 2023 and the balance is expected to be paid by the end of 2023. Activity related to the Restructuring Plan for the nine months ended September 30, 2023 was as follows (amounts in thousands): Restructuring Costs Amounts Paid in the Nine Months Ended September 30, 2023 Non-Cash Restructuring Items Restructuring Liability Severance & employee-related costs $ 2,830 $ ( 2,478 ) $ ( 214 ) $ 138 Inventory write-off 17,185 — $ ( 17,185 ) — Accelerated depreciation 3,816 — $ ( 3,816 ) — Facility exit and other exit costs 181 ( 171 ) $ ( 10 ) — Total $ 24,012 $ ( 2,649 ) $ ( 21,225 ) $ 138

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Revenue Recognition	6. Revenue Recognition Disaggregation of Revenue Revenues for the three and nine months ended September 30, 2023 and 2022 were as follows: Three Months Ended Nine Months Ended 2023 2022 2023 2022 (Amounts in thousands) (As Restated) Product revenue $ 141,156 $ 200,708 $ 465,630 $ 614,668 Royalty and other income 36 33 111 106 Total revenue $ 141,192 $ 200,741 $ 465,741 $ 614,774 When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. Because substantially all of its revenues are from bioprocessing customers, there are no differences in the nature, timing and uncertainty of the Company’s revenues and cash flows from any of its product lines. However, given that the Company’s revenues are generated in different geographic regions, regulatory, economic and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. In addition, a significant portion of the Company’s revenue is generated from a small number of customers; therefore, economic factors specific to these customers could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Disaggregated revenue from contracts with customers by geographic region and revenue from significant customers can be found in Note 15, “Segment Reporting,” included in this report. For more information regarding our product revenue, see Note 6, “Revenue Recognition” included in Part II, Item 8, “ Financial Statements and Supplementary Data” to our Form 10-K. Contract Balances from Contracts with Customers The following table provides information about receivables and deferred revenue from contracts with customers as of September 30, 2023 (amounts in thousands): September 30, December 31, 2023 2022 Balances from contracts with customers only: (As Restated) Accounts receivable $ 106,158 $ 116,247 Deferred revenue (included in accrued liabilities and $ 28,522 $ 19,631 Revenue recognized during periods presented relating to: The beginning deferred revenue balance $ 16,999 $ 13,390 The timing of revenue recognition, billings and cash collections results in the accounts receivable and deferred revenue balances on the Company’s condensed consolidated balance sheets.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2023
Goodwill And Other Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	7. Goodwill and Intangible Assets (As Restated) Goodwill The following table represents the change in the carrying value of goodwill for the nine months ended September 30, 2023 (amounts in thousands): Balance at December 31, 2022 $ 855,513 Acquisition of FlexBiosys, Inc. 14,355 Measurement period adjustment – FlexBiosys ( 34 ) Cumulative translation adjustment ( 582 ) Balance at September 30, 2023 $ 869,252 During each of the fourth quarters of 2022, 2021 and 2020, the Company completed its annual assessments and concluded that goodwill was not impaired in any of those years. The Company has not identified any "triggering" events which indicate an impairment of goodwill in the three and nine months ended September 30, 2023. Intangible Assets (As Restated) Indefinite-lived intangible assets are reviewed for impairment at least annually. There has been no impairment of the Company’s intangible assets for the periods presented. Intangible assets, net, consisted of the following at September 30, 2023: September 30, 2023 Gross Accumulated Net Weighted (Amounts in thousands) Finite-lived intangible assets: (As Restated) (As Restated) (As Restated) Technology – developed $ 207,130 $ ( 40,446 ) $ 166,684 16 Patents 240 ( 240 ) — 8 Customer relationships 255,113 ( 78,929 ) 176,184 15 Trademarks 7,709 ( 1,653 ) 6,056 19 Other intangibles 3,026 ( 2,332 ) 694 4 Total finite-lived intangible assets 473,218 ( 123,600 ) 349,618 16 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 473,918 $ ( 123,600 ) $ 350,318 Intangible assets, net, consisted of the following at December 31, 2022: December 31, 2022 Gross Accumulated Net Weighted (Amounts in thousands) Finite-lived intangible assets: (As Revised) (As Revised) Technology – developed $ 197,405 $ ( 30,992 ) $ 166,413 16 Patents 240 ( 240 ) — 8 Customer relationships 252,934 ( 66,559 ) 186,375 15 Trademarks 7,682 ( 1,319 ) 6,363 19 Other intangibles 2,811 ( 2,044 ) 767 4 Total finite-lived intangible assets 461,072 ( 101,154 ) 359,918 16 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 461,772 $ ( 101,154 ) $ 360,618 Amortization expense for finite-lived intangible assets was $ 7.6 million and $ 6.6 million for each of the three months ended September 30, 2023 and 2022 , respectively, and $ 22.8 million and $ 19.8 million for each of the nine months ended September 30, 2023 and 2022 , respectively. As of September 30, 2023, the Company expects to record the following amortization expense in future periods (amounts in thousands): Estimated Amortization Expense For the Years Ended December 31, (As Restated) 2023 (remaining three months) $ 7,622 2024 30,029 2025 29,691 2026 29,663 2027 29,630 2028 and thereafter 222,983 Total $ 349,618

Consolidated Balance Sheet Deta

Consolidated Balance Sheet Detail	9 Months Ended
	Sep. 30, 2023
Disclosure Text Block [Abstract]
Consolidated Balance Sheet Detail	8. Consolidated Balance Sheet Detail Inventories, net Inventories, net consists of the following: September 30, December 31, 2023 2022 (Amounts in thousands) Raw materials $ 128,894 $ 149,438 Work-in-process 5,630 6,183 Finished products 76,848 82,656 Total inventories, net $ 211,372 $ 238,277 Property, Plant and Equipment Property, plant and equipment consist of the following: September 30, December 31, 2023 2022 (Amounts in thousands) Land $ 950 $ 1,003 Buildings 1,637 1,599 Leasehold improvements 124,925 115,672 Equipment 111,625 94,613 Furniture, fixtures and office equipment 8,786 8,307 Computer hardware and software 35,359 29,813 Construction in progress 37,679 31,553 Other 410 420 Total property, plant and equipment 321,371 282,980 Less – Accumulated depreciation ( 119,753 ) ( 92,307 ) Total property, plant and equipment, net $ 201,618 $ 190,673 Accrued Liabilities Accrued liabilities consist of the following: September 30, December 31, 2023 2022 (Amounts in thousands) (As Restated) Employee compensation $ 13,727 $ 33,522 Deferred revenue 27,954 19,283 Income taxes payable 946 2,459 Other 15,491 15,856 Total accrued liabilities $ 58,118 $ 71,120

Convertible Senior Notes

Convertible Senior Notes	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Convertible Senior Notes	9. Convertible Senior Notes 0.375% Convertible Senior Notes due 2024 On July 19, 2019, the Company issued $ 287.5 million aggregate principal pursuant to the 2019 Notes, which includes the underwriters’ exercise in full of an option to purchase an additional $ 37.5 million aggregate principal amount of 2019 Notes (the “Notes Offering”). The net proceeds of the Notes Offering, after deducting underwriting discounts and commissions and other related offering expenses payable by the Company, were approximately $ 278.5 million. The 2019 Notes are senior, unsecured obligations of the Company, and bear interest at a rate of 0.375 % per year. Interest is payable semi-annually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020. The 2019 Notes will mature on July 15, 2024 , unless earlier repurchased or converted in accordance with their terms. During the third quarter of 2023, the closing price of the Company’s common stock exceeded 130 % of the conversion price of the 2019 Notes for more than 20 trading days of the last 30 consecutive trading days of the quarter. As a result, the 2019 Notes are convertible at the option of the holders of the 2019 Notes during the fourth quarter of 2023, the quarter immediately following the quarter when the conditions are met, as stated in the terms of the 2019 Notes. These conditions have been met each quarter since the third quarter of 2020. As a result, $ 0.1 million aggregate principal amount of the 2019 Notes have been requested for conversion by the note holders since the issuance of the 2019 Notes and all conversions have settled as of September 30, 2023. The conversions resulted in the issuance of a nominal number of shares of the Company’s common stock to the note holders. Because the 2019 Notes mature within one year of the report date, the Company classifies the carrying value of the 2019 Notes as current liabilities on the Company’s condensed consolidated balance sheets at September 30, 2023. The net carrying value of the liability component of the 2019 Notes is as follows: September 30, December 31, (Amounts in thousands) 0.375% Convertible Senior Notes due 2024: Principal amount $ 287,437 $ 287,470 Unamortized debt issuance costs ( 1,481 ) ( 2,855 ) Net carrying amount $ 285,956 $ 284,615 The following table sets forth total interest expense recognized related to the 2019 Notes: Three Months Ended Nine Months Ended 2023 2022 2023 2022 (Amounts in thousands) Contractual interest expense $ 269 $ 270 $ 808 $ 809 Amortization of debt issuance costs 459 455 1,373 1,360 Total $ 728 $ 725 $ 2,181 $ 2,169 Effective interest rate of the liability component 1.0 % 1.0 % 1.0 % 1.0 % At September 30, 2023 and December 31, 2022, the carrying value of the 2019 Notes was $ 286.0 million and $ 284.6 million, respectively, net of unamortized discount, and the fair value of the 2019 Notes was $ 405.3 million and $ 452.0 million, respectively. The fair value of the 2019 Notes was determined based on the most recent trade activity of the 2019 Notes at September 30, 2023 and December 31, 2022 .

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Stockholders' Equity	10. Stockholders’ Equity Stock Option and Incentive Plans Under the Company’s current 2018 Stock Option and Incentive Plan (the “2018 Plan”), the number of shares of the Company’s common stock that were reserved and available for issuance is 2,778,000 , plus the number of shares of common stock that were available for issuance under the Company’s previous equity plans. The shares of common stock underlying any awards under the 2018 Plan and previous equity plans (together, the “Plans”) that are forfeited, canceled or otherwise terminated (other than by exercise) shall be added back to the shares of stock available for issuance under the 2018 Plan. At September 30, 2023, 1,704,118 shares were available for future grants under the 2018 Plan. Stock Issued for Earnout Payment In May 2023, the Company issued 42,621 shares of its common stock to former securityholders of Avitide to satisfy the contingent consideration obligation established under the Agreement and Plan of Merger and Reorganization (the "Avitide Agreement") which the Company entered into as part of the acquisition of Avitide in September 2021. See Note 4, "Acquisitions", included in Part II, Item 8 "Financial Statements and Supplemental Data" to our Form 10-K, for additional information on the acquisition of Avitide and the contingent consideration. The shares represent 50 % of the earnout consideration earned in the First Earnout Year (as defined in the Avitide Agreement). Stock-Based Compensation The following table presents stock-based compensation expense in the Company’s condensed consolidated statements of comprehensive income: Three Months Ended Nine Months Ended 2023 2022 2023 2022 (Amounts in thousands) Cost of product revenue $ 393 $ 610 $ 1,506 $ 1,847 Research and development 700 534 2,095 1,955 Selling, general and administrative 5,280 5,010 15,509 17,252 Total stock-based compensation $ 6,373 $ 6,154 $ 19,110 $ 21,054 Stock Options Information regarding option activity for the nine months ended September 30, 2023 under the Plans is summarized below: Shares Weighted Weighted- Aggregate Options outstanding at December 31, 2022 609,965 $ 71.74 Granted 66,069 $ 173.08 Exercised ( 22,872 ) $ 15.52 Forfeited/expired/cancelled ( 2,000 ) $ 199.71 Options outstanding at September 30, 2023 651,162 $ 83.60 Options exercisable at September 30, 2023 371,782 $ 61.46 Vested and expected to vest at September 30, 2023 (1) 637,673 $ 83.18 5.73 $ 53,173 (1) Represents the number of vested options as of September 30, 2023 plus the number of unvested options expected to vest as of September 30, 2023 based on the unvested outstanding options at September 30, 2023 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees. The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the closing price of the common stock on September 30, 2023, the last business day of the third quarter of 2023, of $ 159.01 per share and the exercise price of each in-the-money option) that would have been received by the option holders had all option holders exercised their options on September 30, 2023. The aggregate intrinsic value of stock options exercised during the nine months ended September 30, 2023 and 2022 was $ 3.4 million and $ 9.8 million, respectively. The weighted average grant date fair value of options granted during the nine months ended September 30, 2023 and 2022 was $ 85.70 and $ 76.64 , respectively. Stock Units The fair value of stock units is calculated using the closing price of the Company’s common stock on the date of grant. The Company recognizes expense on awards with service-based vesting over the employee’s requisite service period on a straight-line basis. The Company recognizes expense on performance-based awards over the vesting period based on the probability that the performance metrics will be achieved. Information regarding stock unit activity, which includes activity for restricted stock units and performance stock units, for the nine months ended September 30, 2023 under the Plans is summarized below: Shares Weighted Average Unvested at December 31, 2022 531,034 $ 142.57 Awarded 175,475 $ 174.86 Vested ( 173,714 ) $ 118.70 Forfeited/cancelled ( 53,920 ) $ 179.53 Unvested at September 30, 2023 478,875 $ 188.41 Vested and expected to vest at September 30, 2023 (1) 411,646 $ 153.79 (1) Represents the number of vested stock units as of September 30, 2023 plus the number of unvested stock units expected to vest as of September 30, 2023 based on the unvested outstanding stock units at September 30, 2023 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees. The aggregate intrinsic value of stock units vested during the nine months ended September 30, 2023 and 2022 was $ 32.3 million and $ 40.4 million, respectively. The weighted average grant date fair value of stock units granted during the nine months ended September 30, 2023 and 2022 was $ 174.86 and $ 191.55 , respectively. As of September 30, 2023, there was $ 66.0 million of total unrecognized compensation cost related to unvested share-based awards. This cost is expected to be recognized over a weighted average remaining requisite service period of 2.88 years. The Company expects 2,156,681 unvested options and stock units to vest over the next five years .

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Collaboration Agreements The Company licenses certain technologies that are, or may be, incorporated into its technology under several agreements and also has entered into several clinical research agreements that require the Company to fund certain research projects. Generally, the license agreements require the Company to pay annual maintenance fees and royalties on product sales once a product has been established using the technologies. Research and development expenses associated with license agreements were immaterial amounts for the three and nine months ended September 30, 2023 and 2022. In June 2018, the Company secured an agreement with Navigo Proteins GmbH (“Navigo”) for the exclusive co-development of multiple affinity ligands for which the Company holds commercialization rights. The Company is manufacturing and supplying the first of these ligands, NGL-Impact ® , exclusively to Purolite Life Sciences, an Ecolab Inc. company (“Purolite”), who is pairing the Company’s high-performance ligand with Purolite’s agarose jetting base bead technology used in their Jetted A50 Protein A resin product. The Company also signed a long-term supply agreement with Purolite for NGL-Impact and other potential additional affinity ligands that may advance from the Company’s Navigo collaboration. In September 2020, the Company and Navigo successfully completed co-development of an affinity ligand targeting the SARS-CoV-2 spike protein, to be utilized in the purification of vaccines for the COVID-19 pandemic, including emerging variants of the SARS-CoV-2 coronavirus. The Company has proceeded with scaling up and manufacturing this ligand and the development and validation of the related affinity chromatography resin, which is marketed by the Company. In September 2021, the Company and Navigo successfully completed co-development of a novel affinity ligand that addresses aggregation issues associated with pH sensitive antibodies and Fc-fusion proteins. The Company is manufacturing and supplying this ligand, NGL-Impact ® HipH, to Purolite. The Navigo and Purolite agreements are supportive of the Company’s strategy to secure and reinforce the Company’s proteins business. The Company made royalty payments to Navigo of $ 0.8 million and $ 0.4 million for the three months ended September 30, 2023 and 2022 , respectively, and payments of $ 3.1 million and $ 1.5 million for the nine months ended September 30, 2023 and 2022, respectively. Legal Proceedings From time to time, in the normal course of its operations, the Company is subject to litigation matters and claims relating to employee relations, business practices and patent infringement. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict, and the Company's view of these matters may change in the future as the litigation and events related thereto unfold. The Company expenses legal fees as incurred. The Company records a provision for contingent losses when it is both probably that a liability has been incurred and the amount of the loss can be reasonably estimated. An unfavorable outcome to any legal matter, if material, could have an adverse effect on the Company's operations or its financial results.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes (As Restated) For the three and nine months ended September 30, 2023, the Company recorded an income tax benefit of $ ( 5.5 ) million and an income tax provision of $ 2.8 million, respectively. The Company’s effective tax rate for the three and nine months ended September 30, 2023 was ( 48.7 %) and 5.1 % , respectively, compared to 14.9 % and 17.4 % for the corresponding periods in the prior year. On August 16, 2022, the United States enacted the Inflation Reduction Act of 2022 ("Inflation Reduction Act"), which, among other things, implements a 15 % alternative minimum tax on global adjusted financial statement income of certain large corporations, a 1 % excise tax on net stock repurchases and several tax incentives to promote clean energy and was effective beginning in 2023. We evaluated the provisions of the Inflation Reduction Act and no provision had a material effect on our consolidated financial position or results of operations.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share, Basic [Abstract]
Earnings Per Share	13. Earnings Per Share A reconciliation of basic and diluted weighted average shares outstanding is as follows: Three Months Ended Nine Months Ended 2023 2022 2023 2022 (Amounts in thousands, except per share data) Numerator: (As Restated) (As Restated) Net income $ 16,923 $ 40,405 $ 52,046 $ 137,230 Effect of dilutive securities: Charges associated with convertible debt instruments, net of tax — — — 387 Numerator for diluted earnings per share – net income available to common stockholders after the effect of dilutive securities $ 16,923 $ 40,405 $ 52,046 $ 137,617 Denominator: Weighted average shares used in computing net income per share – basic 55,766 55,498 55,688 55,432 Effect of dilutive shares: Options and stock units 439 673 469 663 Convertible Senior Notes 735 1,131 776 1,501 Dilutive effect of unvested performance stock units - 2 - 2 Dilutive potential common shares 1,174 1,806 1,245 2,166 Denominator for diluted earnings per share – adjusted weighted average shares used in computing net income per share – diluted 56,940 57,304 56,933 57,598 Earnings per share: Basic $ 0.30 $ 0.73 $ 0.93 $ 2.48 Diluted $ 0.30 $ 0.71 $ 0.91 $ 2.39 For the three and nine months ended September 30, 2023, 301,404 shares and 328,179 shares, respectively, of the Company’s common stock were excluded from the calculation of diluted EPS because the exercise prices of the stock options were greater than or equal to the average price of the common shares and were therefore anti-dilutive. Comparatively, for the three and nine months ended September 30, 2022, 112,179 shares and 149,187 shares, respectively, were considered anti-dilutive. In July 2019, the Company issued $ 287.5 million aggregate principal amount of the 2019 Notes. As provided by the terms of the indenture underlying the 2019 Notes, prior to March 4, 2022, conversion of the 2019 Notes could have been settled in cash, shares of the Company’s common stock or a combination thereof, at the Company’s election. On March 4, 2022, we entered into the Second Supplemental Indenture for the 2019 Notes, which irrevocably elected to settle the conversion of the 2019 Notes using a combination of cash and shares of the Company’s common stock, settling the par value of the 2019 Notes in cash and any excess conversion premium in shares. As provided by the terms of the Second Supplemental Indenture underlying the 2019 Notes, the Company irrevocably elected to settle the conversion obligation for the 2019 Notes in a combination of cash and shares of the Company's common stock. This means the Company will settle the par value of the 2019 Notes in cash and any excess conversion premium in shares. The Company adopted ASU 2020-06 effective January 1, 2022. Under ASU 2020-06, the Company is required to reflect the dilutive effect of the convertible securities by application of the "if-converted" method, which means the denominator of the EPS calculation would include the total number of shares assuming the 2019 Notes had been fully converted at the beginning of the period. Prior to March 4, 2022, the Company had the choice to settle the conversion of the 2019 Notes in cash, stock or a combination of the two. Therefore, from January 1, 2022 (the date the Company adopted ASU 2020-06) to March 4, 2022, the Company included 3,474,429 shares in the denominator of the EPS calculation, applying the if converted method. Subsequent to March 4, 2022, after the Second Supplemental Indenture became effective, the Company irrevocably elected to settle the conversion obligation for the 2019 Notes in a combination of cash and shares of the Company's common stock, and from March 5, 2022 forward, only the excess premium will be settled with shares. Under the if-converted method of calculating dilutive shares, the Company was also required to exclude amortization of debt issuance costs and interest charges applicable to the convertible debt from the numerator of the dilutive EPS calculation for the period from January 1, 2022 to March 4, 2022, as if the interest on convertible debt was never recognized for that period. For the three months ended March 31, 2022, the Company excluded interest charges of $ 0.4 million (net of tax) from the numerator. Prior to the adoption of ASU 2020-06, the Company applied the provisions of ASC 260, “Earnings Per Share,” Subsection 10-45-44, to determine the diluted weighted average shares outstanding as it related to the conversion spread on its convertible notes. Accordingly, the par value of the 2019 Notes was not included in the calculation of diluted income per share, but the dilutive effect of the conversion premium was considered in the calculation of diluted net income per share using the treasury stock method. The dilutive impact of the 2019 Notes was based on the difference between the Company’s current period average stock price and the conversion price of the 2019 Notes, provided there was a premium. Pursuant to this accounting standard, there was no dilution from the accreted principal of the 2019 Notes. For the three and nine months ended September 30, 2023, the dilutive effect of the conversion premium included in the calculation of diluted earnings was 735,150 shares and 776,339 shares, respectively. For the three and nine months ended September 30, 2022, the dilutive effect of the conversion premium included in the calculation of diluted earnings was 1,130,530 shares and 1,500,717 shares, respectively.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	14. Related Party Transactions Certain facilities leased by our subsidiary, Spectrum LifeSciences LLC ("Spectrum") are owned by the Roy T. Eddleman Living Trust (the "Trust"). As of September 30, 2023 , the Trust owned greater than 5 % of the Company’s outstanding shares. Therefore, the Company considers the Trust to be a related party. The lease amounts paid to the Trust prior to the public offering were negotiated in connection with the acquisition of Spectrum. The Company incurred rent expense totaling $ 0.1 million and $ 0.2 million respectively for each of the three months ended September 30, 2023 and 2022 related to these leases and incurred rent expense of $ 0.5 million for each of the nine months ended September 30, 2023 and 2022 .

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Segment Reporting	15. Segment Reporting Operating segments are components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker ("CODM") in deciding how to allocate resources and assess performance. Our Chief Executive Officer ("CEO") has been identified as the CODM. The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one operating segment and one reportable segment. Our CODM evaluates financial information on a consolidated basis. As a result, the required financial segment information can be found in the consolidated condensed financial statements of the Company disclosed herein. The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Revenue by customers' geographic locations: (As Restated) North America 49 % 42 % 46 % 42 % Europe 34 % 35 % 34 % 38 % APAC/Other 17 % 23 % 20 % 20 % Total revenue 100 % 100 % 100 % 100 % Concentrations of Credit Risk and Significant Customers (As Restated) Financial instruments that subject the Company to significant concentrations of credit risk primarily consist of cash and cash equivalents, marketable securities and accounts receivable. Per the Company’s investment policy, cash equivalents and marketable securities are invested in financial instruments with high credit ratings and credit exposure to any one issue, issuer (with the exception of U.S. Treasury obligations) and type of instrument is limited. At September 30, 2023 and December 31, 2022, the Company had no investments associated with foreign exchange contracts, options contracts or other foreign hedging arrangements. Concentration of credit risk with respect to accounts receivable is limited to customers to whom the Company makes significant sales. While a reserve for the potential write-off of accounts receivable is maintained, the Company has not written off any significant accounts to date. To control credit risk, the Company performs regular credit evaluations of its customers’ financial condition. There was no revenue from customers that represented 10 % or more of the Company's total revenue for the three and nine months ended September 30, 2023 and 2022. No accounts receivable balance from a specific customer represented 10 % or more of the Company's total trade accounts receivable at September 30, 2023 . Significant accounts receivable balances representing 10 % or more of the Company's accounts receivable and royalties at December 31, 2022 came from our accounts receivable balance outstanding with Purolite, an Ecolab Inc. company, which was 12.7 % of our total trade accounts receivable balance.

Subsequent Event

Subsequent Event	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent Event	16. Subsequent Event Acquisition of Metenova Holding AB On October 2, 2023 , Repligen Sweden AB, a subsidiary of the Company completed its acquisition of all of the outstanding equity interests in Metenova Holding AB ("Metenova"), pursuant to a Share Sale and Purchase Agreement with, inter alia, Metenova for approximately $ 173 million in cash and the Company's equity. Metenova will further strengthen our fluid management portfolio with its magnetic mixing and drive train technologies that are widely used by global biopharmaceutical companies and contract development and manufacturing organizations. The Company will account for the acquisition of Metenova as a purchase of business under the acquisition method of accounting and has engaged a third-party valuation firm to assist with the valuation of the business acquired. The estimated purchase price allocation for the acquisition of Metenova will be included in the Annual Report on Form 10-K for the year ended December 31, 2023.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of presentation	Basis of Presentation The condensed consolidated financial statements included herein have been prepared by Repligen Corporation in accordance with generally accepted accounting principles accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and footnote disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on February 22, 2023 (“Form 10-K”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The business and economic uncertainty resulting from government-mandated actions in response to the COVID-19 pandemic, including all subsequent variants of the SARS-CoV-2 coronavirus ("COVID-19"), global geopolitical conflicts, supply chain challenges, cost pressure and the overall effects of the current high inflation environment on customers' purchasing patterns has made such estimates more difficult to calculate. Accordingly, actual results could differ from those estimates. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company made no material changes in the application of its significant accounting policies that were disclosed in its Form 10-K. In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of its financial position as of September 30, 2023, its results of operations for the three and nine months ended September 30, 2023 and 2022 and cash flows for the three and nine months ended September 30, 2023 and 2022. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year.
Recent Accounting Standards Updates	Recent Accounting Standards Updates We consider the applicability and impact of all Accounting Standards Updates ("ASU" or "ASUs") on the Company’s condensed consolidated financial statements. As of September 30, 2023, there were no accounting standards or ASUs recently issued or effective during the fiscal year that would have a material effect on the Company's condensed consolidated financial statements or disclosures.

Restatement of Previously Iss_2

Restatement of Previously Issued Financial Statements (Tables)	9 Months Ended
	Sep. 30, 2023
Accounting Changes and Error Corrections [Abstract]
Schedule of Restatement of Previously Issued Financial Statements	September 30, 2023 As Previously Reported Revenue Adjustments Other Adjustments As Restated ASSETS Current assets: Cash and cash equivalents $ 630,779 $ — $ — $ 630,779 Marketable securities held to maturity — — — — Accounts receivable, net of reserves of $ 1,803 and $ 1,365 at 106,158 — — 106,158 Inventories, net 211,372 — — 211,372 Prepaid expenses and other current assets 30,147 2,016 — 32,163 Total current assets 978,456 2,016 — 980,472 Noncurrent assets: Property, plant and equipment, net 201,618 — — 201,618 Intangible assets, net 343,729 — 6,589 350,318 Goodwill 869,252 — — 869,252 Deferred tax assets 1,546 — — 1,546 Operating lease right of use assets 118,084 — — 118,084 Other noncurrent assets 1,444 — — 1,444 Total noncurrent assets 1,535,673 — 6,589 1,542,262 Total assets $ 2,514,129 $ 2,016 $ 6,589 $ 2,522,734 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 18,961 $ — $ — $ 18,961 Operating lease liability 3,315 — — 3,315 Current contingent consideration 12,589 — — 12,589 Accrued liabilities 42,543 15,575 — 58,118 Convertible Senior Notes, net 285,956 — — 285,956 Total current liabilities 363,364 15,575 — 378,939 Noncurrent liabilities: — Deferred tax liabilities 14,036 667 ( 179 ) 14,524 Noncurrent operating lease liability 130,615 — — 130,615 Noncurrent contingent consideration 13,759 — — 13,759 Other noncurrent liabilities 3,798 — 7,356 11,154 Total noncurrent liabilities 162,208 667 7,177 170,052 Total liabilities 525,572 16,242 7,177 548,991 Commitments and contingencies (Note 11) Stockholders' equity: Preferred stock, $ 0.01 par value, 5,000,000 shares authorized, no shares — — — — Common stock, $ 0.01 par value; 80,000,000 shares authorized; 55,774,706 55,557,698 shares at December 31, 2022 558 — — 558 Additional paid-in capital 1,567,233 — — 1,567,233 Accumulated other comprehensive loss ( 43,571 ) 205 — ( 43,366 ) Accumulated earnings 464,337 ( 14,431 ) ( 588 ) 449,318 Total stockholders’ equity 1,988,557 ( 14,226 ) ( 588 ) 1,973,743 Total liabilities and stockholders’ equity $ 2,514,129 $ 2,016 $ 6,589 $ 2,522,734 December 31, 2022 As Previously Reported Other Adjustments As Revised ASSETS Intangible assets, net $ 353,676 $ 6,942 $ 360,618 Total noncurrent assets 1,526,540 6,942 1,533,482 Total assets $ 2,524,658 $ 6,942 $ 2,531,600 LIABILITIES AND STOCKHOLDERS' EQUITY Other noncurrent liabilities $ 3,814 $ 6,942 $ 10,756 Total noncurrent liabilities 209,762 6,942 216,704 Total liabilities 613,958 6,942 620,900 Total liabilities and stockholders’ equity $ 2,524,658 $ 6,942 $ 2,531,600 Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 As Previously Reported Revenue Adjustments Other Adjustments As Restated As Previously Reported Revenue Adjustments Other Adjustments As Restated Revenue: Products $ 141,156 $ — $ — $ 141,156 $ 482,910 $ ( 17,280 ) $ — $ 465,630 Royalty and other revenue 36 — — 36 111 — — 111 Total revenue 141,192 — — 141,192 483,021 ( 17,280 ) — 465,741 Costs and operating expenses: Cost of product revenue 104,634 — — 104,634 265,786 — — 265,786 Research and development 10,577 — — 10,577 32,437 — — 32,437 Selling, general and administrative 55,465 — 117 55,582 160,601 — 353 160,954 Contingent consideration ( 34,292 ) — — ( 34,292 ) ( 31,266 ) — — ( 31,266 ) Total costs and operating expenses 136,384 — 117 136,501 427,558 — 353 427,911 Income from operations 4,808 — ( 117 ) 4,691 55,463 ( 17,280 ) ( 353 ) 37,830 Other income (expenses): Investment income 6,662 — — 6,662 18,112 — — 18,112 Interest expense ( 269 ) — ( 139 ) ( 408 ) ( 813 ) — ( 414 ) ( 1,227 ) Amortization of debt issuance costs ( 459 ) — — ( 459 ) ( 1,373 ) — — ( 1,373 ) Other income (expenses) 895 — — 895 1,500 — — 1,500 Other income (expenses), net 6,829 — ( 139 ) 6,690 17,426 — ( 414 ) 17,012 Income before income taxes 11,637 — ( 256 ) 11,381 72,889 ( 17,280 ) ( 767 ) 54,842 Income tax (benefit) provision ( 6,535 ) 1,053 ( 60 ) ( 5,542 ) 5,824 ( 2,849 ) ( 179 ) 2,796 Net income $ 18,172 $ ( 1,053 ) $ ( 196 ) $ 16,923 $ 67,065 $ ( 14,431 ) $ ( 588 ) $ 52,046 Earnings per share: Basic $ 0.33 $ ( 0.02 ) $ ( 0.01 ) $ 0.30 $ 1.20 $ ( 0.26 ) $ ( 0.01 ) $ 0.93 Diluted (Note 13) $ 0.32 $ ( 0.02 ) $ — $ 0.30 $ 1.18 $ ( 0.25 ) $ ( 0.02 ) $ 0.91 Weighted average common shares outstanding: Basic 55,766 — — 55,766 55,688 — — 55,688 Diluted (Note 13) 56,940 — — 56,940 56,933 — — 56,933 Net income $ 18,172 $ ( 1,053 ) $ ( 196 ) $ 16,923 $ 67,065 $ ( 14,431 ) $ ( 588 ) $ 52,046 Other comprehensive income (loss): Foreign currency translation adjustment ( 6,382 ) 502 — ( 5,880 ) ( 9,177 ) 205 — ( 8,972 ) Comprehensive income $ 11,790 $ ( 551 ) $ ( 196 ) $ 11,043 $ 57,888 $ ( 14,226 ) $ ( 588 ) $ 43,074 Accumulated Other Comprehensive Loss Accumulated Earnings Total Stockholders' Equity As Previously Reported Revenue Adjustments Other Adjustments As Restated As Previously Reported Revenue Adjustments Other Adjustments As Restated As Previously Reported Revenue Adjustments Other Adjustments As Restated $ $ $ $ $ $ $ $ $ $ $ $ Balance at June 30, 2023 ( 37,189 ) ( 297 ) — ( 37,486 ) 446,165 ( 13,378 ) ( 392 ) 432,395 1,970,926 ( 13,675 ) ( 392 ) 1,956,859 Net income — — — — 18,172 ( 1,053 ) ( 196 ) 16,923 18,172 ( 1,053 ) ( 196 ) 16,923 Translation adjustment ( 6,382 ) 502 — ( 5,880 ) — — — — ( 6,382 ) 502 — ( 5,880 ) Balance at September 30, 2023 ( 43,571 ) 205 — ( 43,366 ) 464,337 ( 14,431 ) ( 588 ) 449,318 1,988,557 ( 14,226 ) ( 588 ) 1,973,743 Accumulated Other Comprehensive Loss Accumulated Earnings Total Stockholders' Equity As Previously Reported Revenue Adjustments Other Adjustments As Restated As Previously Reported Revenue Adjustments Other Adjustments As Restated As Previously Reported Revenue Adjustments Other Adjustments As Restated $ $ $ $ $ $ $ $ $ $ $ $ Balance at December 31, 2022 ( 34,394 ) — — ( 34,394 ) 397,272 — — 397,272 1,910,700 — — 1,910,700 Net income — — — — 67,065 ( 14,431 ) ( 588 ) 52,046 67,065 ( 14,431 ) ( 588 ) 52,046 Translation adjustment ( 9,177 ) 205 — ( 8,972 ) — — — — ( 9,177 ) 205 — ( 8,972 ) Balance at September 30, 2023 ( 43,571 ) 205 — ( 43,366 ) 464,337 ( 14,431 ) ( 588 ) 449,318 1,988,557 ( 14,226 ) ( 588 ) 1,973,743 Nine Months Ended September 30, 2023 As Previously Reported Revenue Adjustments Other Adjustments As Restated Cash flows from operating activities: Net income $ 67,065 $ ( 14,431 ) $ ( 588 ) $ 52,046 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 50,942 — 353 51,295 Amortization of debt issuance costs 1,373 — — 1,373 Stock-based compensation 19,110 — — 19,110 Deferred income taxes, net ( 9,756 ) 667 ( 179 ) ( 9,268 ) Contingent consideration ( 31,266 ) — — ( 31,266 ) Non-cash interest income ( 2,023 ) — — ( 2,023 ) Operating lease right of use asset amortization 10,203 — — 10,203 Other 861 — 414 1,275 Changes in operating assets and liabilities, excluding impact of acquisitions: Accounts receivable 8,315 — — 8,315 Inventories 25,979 — — 25,979 Prepaid expenses and other assets ( 10,733 ) ( 2,016 ) — ( 12,749 ) Other assets ( 707 ) — — ( 707 ) Accounts payable ( 8,619 ) — — ( 8,619 ) Accrued expenses ( 28,294 ) 15,780 — ( 12,514 ) Operating lease liabilities ( 7,676 ) — — ( 7,676 ) Long-term liabilities 79 — — 79 Total cash provided by operating activities 84,853 — — 84,853 Cash flows from investing activities: Acquisitions, net of cash acquired ( 27,843 ) — — ( 27,843 ) Proceeds from maturity of marketable securities held to maturity 102,323 — — 102,323 Additions to capitalized software costs ( 2,736 ) — — ( 2,736 ) Purchases of property, plant and equipment ( 25,135 ) — — ( 25,135 ) Purchase of intellectual property — — — — Other investing activities 21 — — 21 Total cash provided by (used in) investing activities 46,630 — — 46,630 Cash flows from financing activities: Proceeds from exercise of stock options 356 — — 356 Payment of tax withholding obligation on vesting of restricted stock ( 12,178 ) — — ( 12,178 ) Repayment of Convertible Senior Notes ( 33 ) — — ( 33 ) Payment of earnout consideration ( 7,298 ) — — ( 7,298 ) Proceeds from issuance of common stock, net ( 13 ) — — ( 13 ) Total cash used in financing activities ( 19,166 ) — — ( 19,166 ) Effect of exchange rate changes on cash and cash equivalents ( 4,996 ) — — ( 4,996 ) Net increase (decrease) in cash and cash equivalents 107,321 — — 107,321 Cash, cash equivalents and restricted cash, beginning of period 523,458 — — 523,458 Cash and cash equivalents, end of period $ 630,779 $ — $ — $ 630,779 Supplemental disclosure of non-cash investing and financing activities: Assets acquired under operating leases $ 1,129 $ — $ — $ 1,129 Fair value of 31,415 shares of common stock issued for the acquisition of $ 5,465 $ — $ — $ 5,465 Fair value of 42,621 shares of common stock issued for the Avitide, Inc. $ 7,229 $ — $ — $ 7,229 Nine Months Ended September 30, 2022 As Previously Reported Other Adjustments As Revised Cash flows from operating activities: Adjustments to reconcile net income to net cash provided by operating activities: Operating lease right of use asset amortization $ ( 22,033 ) $ 27,705 $ 5,672 Changes in operating assets and liabilities, excluding impact of acquisitions: Operating lease liabilities $ 26,157 $ ( 27,705 ) $ ( 1,548 ) Total cash provided by operating activities $ 110,201 $ — $ 110,201

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Summary of Cash, Cash Equivalents and Marketable Securities Held to Maturity	The following table summarizes the Company's cash, cash equivalents and marketable securities held to maturity as of September 30, 2023 and December 31, 2022 (amounts in thousands): As of September 30, 2023 Amortized Gross Gross Estimated Cash and cash equivalents: Cash and money market funds $ 630,779 $ — $ — $ 630,779 Total cash and cash equivalents $ 630,779 $ — $ — $ 630,779 As of December 31, 2022 Amortized Gross Gross Estimated Cash and cash equivalents: Cash and money market funds $ 523,458 $ — $ — $ 523,458 Total cash and cash equivalents 523,458 — — 523,458 Marketable securities held to maturity: U.S. treasury bills – short-term 100,299 24 — 100,323 Total cash, cash equivalents and marketable securities $ 623,757 $ 24 $ — $ 623,781
Schedule of Amortized Cost and Fair Value Held to Maturity Securities by Contractual Maturity	The amortized cost and the fair value of the Company's held to maturity securities by contractual maturity at December 31, 2022 is summarized below: December 31, 2022 Amortized Estimated Maturity of one year or less $ 100,299 $ 100,323 Total $ 100,299 $ 100,323
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of September 30, 2023 and December 31, 2022 (amounts in thousands): As of September 30, 2023 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 389,473 $ — $ — $ 389,473 Liabilities: Short-term contingent consideration $ — $ — $ 12,589 $ 12,589 Long-term contingent consideration $ — $ — $ 13,759 $ 13,759 As of December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 343,929 $ — $ — $ 343,929 Liabilities: Short-term contingent consideration $ — $ — $ 13,950 $ 13,950 Long-term contingent consideration $ — $ — $ 51,559 $ 51,559
Schedule of Reconciliation of the Change in the Fair Value of Contingent Consideration - Earnout	A reconciliation of the change in the fair value of contingent consideration – earnouts is included in the following table (amounts in thousands): Balance at December 31, 2022 $ 65,509 Acquisition date fair value of contingent consideration earnout 6,632 Payment of contingent consideration earnout ( 14,527 ) Decrease in fair value of contingent consideration earnouts ( 31,266 ) Balance at September 30, 2023 $ 26,348
Schedule of Contingent Consideration Earnout Expect to be Required to Settle Include Significant Unobservable Inputs	The recurring Level 3 fair value measurement of our contingent consideration earnout that we expect to be required to settle our 2023, 2024 and 2025 contingent consideration obligations for Avitide and FlexBiosys include the following significant unobservable inputs (amounts in thousands, except percent data): Contingent Consideration Earnout Fair Value as of Valuation Technique Unobservable Input Range Weighted Average (1) Probability of Success 100 % 100 % Commercialization-based payments $ 19,383 Monte Carlo Earnout Discount Rate 7.1 % 7.1 % Volatility 13.1 %- 24.6 % 21.7 % Revenue and Volume- $ 1,460 Monte Carlo Revenue & Volume 5.1 %- 9.3 % 8.2 % Earnout Discount Rate 6.1 %- 7.1 % 6.5 % Probability of 100 % 100 % Manufacturing line expansions $ 5,505 Probability-weighted present value Earnout Discount Rate 6.1 %- 6.4 % 6.3 % Unobservable inputs were weighted by the relative fair value of the contingent consideration liability.

Acquisition of FlexBiosys, Inc

Acquisition of FlexBiosys, Inc (Tables) - FlexBiosys	9 Months Ended
	Sep. 30, 2023
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The components and estimated allocation of the purchase price consist of the following (amounts in thousands): Cash and cash equivalents $ 1,090 Accounts receivable 683 Inventory 667 Prepaid expenses and other current assets 35 Property and equipment 12,034 Operating lease right of use asset 3,537 Customer relationships 2,530 Developed technology 9,860 Trademark and tradename 30 Non-competition agreements 220 Goodwill 14,321 Other long-term assets 10 Accounts payable ( 136 ) Accrued liabilities ( 314 ) Operating lease liability ( 39 ) Operating lease liability, long-term ( 3,498 ) Fair value of net assets acquired $ 41,030
Schedule of Identified Intangible Assets and Estimated Useful Lives	The following table sets forth the components of the identified intangible assets associated with the FlexBiosys Acquisition and their estimated useful lives: Useful life Fair Value (Amounts in thousands) Customer relationships 12 years $ 2,530 Developed technology 16 years 9,860 Trademark and tradename 4 years 30 Non-competition agreements 5 years 220 $ 12,640

Restructuring Plan (Tables)

Restructuring Plan (Tables)	9 Months Ended
	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Summary of Restructuring Activities by Type of Cost	The following table summarizes the charges related to restructuring activities by type of cost: Three and Nine Months Ended September 30, 2023 Severance & Employee-Related Costs Inventory Write-Off Accelerated Depreciation Facility and Other Exit Costs Total (Amounts in thousands) Cost of product revenue $ 1,654 $ 17,185 $ 3,788 $ 84 $ 22,711 Research and development 34 — 1 — 35 Selling, general and administrative 1,142 — 27 97 1,266 $ 2,830 $ 17,185 $ 3,816 $ 181 $ 24,012
Summary of Activity Related to Restructuring Plan	Activity related to the Restructuring Plan for the nine months ended September 30, 2023 was as follows (amounts in thousands): Restructuring Costs Amounts Paid in the Nine Months Ended September 30, 2023 Non-Cash Restructuring Items Restructuring Liability Severance & employee-related costs $ 2,830 $ ( 2,478 ) $ ( 214 ) $ 138 Inventory write-off 17,185 — $ ( 17,185 ) — Accelerated depreciation 3,816 — $ ( 3,816 ) — Facility exit and other exit costs 181 ( 171 ) $ ( 10 ) — Total $ 24,012 $ ( 2,649 ) $ ( 21,225 ) $ 138

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Disaggregation of Revenue	Revenues for the three and nine months ended September 30, 2023 and 2022 were as follows: Three Months Ended Nine Months Ended 2023 2022 2023 2022 (Amounts in thousands) (As Restated) Product revenue $ 141,156 $ 200,708 $ 465,630 $ 614,668 Royalty and other income 36 33 111 106 Total revenue $ 141,192 $ 200,741 $ 465,741 $ 614,774
Summary of Receivables and Deferred Revenue from Contracts with Customers	The following table provides information about receivables and deferred revenue from contracts with customers as of September 30, 2023 (amounts in thousands): September 30, December 31, 2023 2022 Balances from contracts with customers only: (As Restated) Accounts receivable $ 106,158 $ 116,247 Deferred revenue (included in accrued liabilities and $ 28,522 $ 19,631 Revenue recognized during periods presented relating to: The beginning deferred revenue balance $ 16,999 $ 13,390

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2023
Goodwill And Other Intangible Assets Disclosure [Abstract]
Changes in Carrying Value of Goodwill	The following table represents the change in the carrying value of goodwill for the nine months ended September 30, 2023 (amounts in thousands): Balance at December 31, 2022 $ 855,513 Acquisition of FlexBiosys, Inc. 14,355 Measurement period adjustment – FlexBiosys ( 34 ) Cumulative translation adjustment ( 582 ) Balance at September 30, 2023 $ 869,252
Schedule of Intangible Assets	Intangible assets, net, consisted of the following at September 30, 2023: September 30, 2023 Gross Accumulated Net Weighted (Amounts in thousands) Finite-lived intangible assets: (As Restated) (As Restated) (As Restated) Technology – developed $ 207,130 $ ( 40,446 ) $ 166,684 16 Patents 240 ( 240 ) — 8 Customer relationships 255,113 ( 78,929 ) 176,184 15 Trademarks 7,709 ( 1,653 ) 6,056 19 Other intangibles 3,026 ( 2,332 ) 694 4 Total finite-lived intangible assets 473,218 ( 123,600 ) 349,618 16 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 473,918 $ ( 123,600 ) $ 350,318 Intangible assets, net, consisted of the following at December 31, 2022: December 31, 2022 Gross Accumulated Net Weighted (Amounts in thousands) Finite-lived intangible assets: (As Revised) (As Revised) Technology – developed $ 197,405 $ ( 30,992 ) $ 166,413 16 Patents 240 ( 240 ) — 8 Customer relationships 252,934 ( 66,559 ) 186,375 15 Trademarks 7,682 ( 1,319 ) 6,363 19 Other intangibles 2,811 ( 2,044 ) 767 4 Total finite-lived intangible assets 461,072 ( 101,154 ) 359,918 16 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 461,772 $ ( 101,154 ) $ 360,618
Schedule of Amortization Expense for Amortized Intangible Assets	As of September 30, 2023, the Company expects to record the following amortization expense in future periods (amounts in thousands): Estimated Amortization Expense For the Years Ended December 31, (As Restated) 2023 (remaining three months) $ 7,622 2024 30,029 2025 29,691 2026 29,663 2027 29,630 2028 and thereafter 222,983 Total $ 349,618

Consolidated Balance Sheet De_2

Consolidated Balance Sheet Detail (Tables)	9 Months Ended
	Sep. 30, 2023
Disclosure Text Block [Abstract]
Inventories	Inventories, net Inventories, net consists of the following: September 30, December 31, 2023 2022 (Amounts in thousands) Raw materials $ 128,894 $ 149,438 Work-in-process 5,630 6,183 Finished products 76,848 82,656 Total inventories, net $ 211,372 $ 238,277
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment consist of the following: September 30, December 31, 2023 2022 (Amounts in thousands) Land $ 950 $ 1,003 Buildings 1,637 1,599 Leasehold improvements 124,925 115,672 Equipment 111,625 94,613 Furniture, fixtures and office equipment 8,786 8,307 Computer hardware and software 35,359 29,813 Construction in progress 37,679 31,553 Other 410 420 Total property, plant and equipment 321,371 282,980 Less – Accumulated depreciation ( 119,753 ) ( 92,307 ) Total property, plant and equipment, net $ 201,618 $ 190,673
Accrued Liabilities	Accrued Liabilities Accrued liabilities consist of the following: September 30, December 31, 2023 2022 (Amounts in thousands) (As Restated) Employee compensation $ 13,727 $ 33,522 Deferred revenue 27,954 19,283 Income taxes payable 946 2,459 Other 15,491 15,856 Total accrued liabilities $ 58,118 $ 71,120

Convertible Senior Notes (Table

Convertible Senior Notes (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Instrument [Line Items]
Carrying Value of Convertible Senior Notes	The net carrying value of the liability component of the 2019 Notes is as follows: September 30, December 31, (Amounts in thousands) 0.375% Convertible Senior Notes due 2024: Principal amount $ 287,437 $ 287,470 Unamortized debt issuance costs ( 1,481 ) ( 2,855 ) Net carrying amount $ 285,956 $ 284,615
2019 Notes
Debt Instrument [Line Items]
Schedule of convertiable note interest expense	The following table sets forth total interest expense recognized related to the 2019 Notes: Three Months Ended Nine Months Ended 2023 2022 2023 2022 (Amounts in thousands) Contractual interest expense $ 269 $ 270 $ 808 $ 809 Amortization of debt issuance costs 459 455 1,373 1,360 Total $ 728 $ 725 $ 2,181 $ 2,169 Effective interest rate of the liability component 1.0 % 1.0 % 1.0 % 1.0 %

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Stock-Based Compensation Expense	The following table presents stock-based compensation expense in the Company’s condensed consolidated statements of comprehensive income: Three Months Ended Nine Months Ended 2023 2022 2023 2022 (Amounts in thousands) Cost of product revenue $ 393 $ 610 $ 1,506 $ 1,847 Research and development 700 534 2,095 1,955 Selling, general and administrative 5,280 5,010 15,509 17,252 Total stock-based compensation $ 6,373 $ 6,154 $ 19,110 $ 21,054
Summary of Option Activity	Information regarding option activity for the nine months ended September 30, 2023 under the Plans is summarized below: Shares Weighted Weighted- Aggregate Options outstanding at December 31, 2022 609,965 $ 71.74 Granted 66,069 $ 173.08 Exercised ( 22,872 ) $ 15.52 Forfeited/expired/cancelled ( 2,000 ) $ 199.71 Options outstanding at September 30, 2023 651,162 $ 83.60 Options exercisable at September 30, 2023 371,782 $ 61.46 Vested and expected to vest at September 30, 2023 (1) 637,673 $ 83.18 5.73 $ 53,173 (1) Represents the number of vested options as of September 30, 2023 plus the number of unvested options expected to vest as of September 30, 2023 based on the unvested outstanding options at September 30, 2023 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.
Summary of Restricted Stock Unit Activity	Information regarding stock unit activity, which includes activity for restricted stock units and performance stock units, for the nine months ended September 30, 2023 under the Plans is summarized below: Shares Weighted Average Unvested at December 31, 2022 531,034 $ 142.57 Awarded 175,475 $ 174.86 Vested ( 173,714 ) $ 118.70 Forfeited/cancelled ( 53,920 ) $ 179.53 Unvested at September 30, 2023 478,875 $ 188.41 Vested and expected to vest at September 30, 2023 (1) 411,646 $ 153.79 (1) Represents the number of vested stock units as of September 30, 2023 plus the number of unvested stock units expected to vest as of September 30, 2023 based on the unvested outstanding stock units at September 30, 2023 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share, Basic [Abstract]
Basic and Diluted Weighted Average Shares Outstanding	A reconciliation of basic and diluted weighted average shares outstanding is as follows: Three Months Ended Nine Months Ended 2023 2022 2023 2022 (Amounts in thousands, except per share data) Numerator: (As Restated) (As Restated) Net income $ 16,923 $ 40,405 $ 52,046 $ 137,230 Effect of dilutive securities: Charges associated with convertible debt instruments, net of tax — — — 387 Numerator for diluted earnings per share – net income available to common stockholders after the effect of dilutive securities $ 16,923 $ 40,405 $ 52,046 $ 137,617 Denominator: Weighted average shares used in computing net income per share – basic 55,766 55,498 55,688 55,432 Effect of dilutive shares: Options and stock units 439 673 469 663 Convertible Senior Notes 735 1,131 776 1,501 Dilutive effect of unvested performance stock units - 2 - 2 Dilutive potential common shares 1,174 1,806 1,245 2,166 Denominator for diluted earnings per share – adjusted weighted average shares used in computing net income per share – diluted 56,940 57,304 56,933 57,598 Earnings per share: Basic $ 0.30 $ 0.73 $ 0.93 $ 2.48 Diluted $ 0.30 $ 0.71 $ 0.91 $ 2.39

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2023
Text Block [Abstract]
Percentage by Geographic Area or Significant Customers	The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Revenue by customers' geographic locations: (As Restated) North America 49 % 42 % 46 % 42 % Europe 34 % 35 % 34 % 38 % APAC/Other 17 % 23 % 20 % 20 % Total revenue 100 % 100 % 100 % 100 %

Restatement of Previously Iss_3

Restatement of Previously Issued Financial Statements - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Accounting Changes and Error Corrections [Abstract]
Cancelled purchase orders in exchange for payment	$ 17.3
Payment to purchase component of product revenue	$ 17.3

Restatement of Previously Iss_4

Restatement of Previously Issued Financial Statements - Schedule of Restatement of Previously Issued Financial Statements - Condensed Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 630,779		$ 523,458
Marketable securities held to maturity	0		100,299
Accounts receivable, net of reserves of $1,803 and $1,365 at September 30, 2023 and December 31, 2022, respectively	106,158		116,247
Inventories, net	211,372		238,277
Prepaid expenses and other current assets	32,163		19,837
Total current assets	980,472		998,118
Noncurrent assets:
Property, plant and equipment, net	201,618		190,673
Intangible assets, net	350,318		360,618
Goodwill	869,252		855,513
Deferred tax assets	1,546		840
Operating lease right of use assets	118,084		125,023
Other noncurrent assets	1,444		815
Total noncurrent assets	1,542,262		1,533,482
Total assets	2,522,734		2,531,600
Current liabilities:
Accounts payable	18,961		27,554
Operating lease liability	3,315		6,957
Current contingent consideration	12,589		13,950
Accrued liabilities	58,118		71,120
Convertible Senior Notes, net	285,956		284,615
Total current liabilities	378,939		404,196
Noncurrent liabilities:
Deferred tax liabilities	14,524		23,000
Noncurrent operating lease liability	130,615		131,389
Noncurrent contingent consideration	13,759		51,559
Other noncurrent liabilities	11,154		10,756
Total noncurrent liabilities	170,052		216,704
Total liabilities	548,991		620,900
Commitments and contingencies (Note 11)
Equity, Attributable to Parent [Abstract]
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding	0		0
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,774,706 shares at September 30, 2023 and 55,557,698 shares at December 31, 2022 issued and outstanding	558		556
Additional paid-in capital	1,567,233		1,547,266
Accumulated other comprehensive loss	(43,366)		(34,394)
Accumulated earnings	449,318		397,272
Total stockholders' equity	1,973,743	$ 1,956,859	1,910,700	$ 1,835,109	$ 1,805,364	$ 1,750,067
Total liabilities and stockholders' equity	2,522,734		2,531,600
As Previously Reported
Current assets:
Cash and cash equivalents	630,779
Marketable securities held to maturity	0
Accounts receivable, net of reserves of $1,803 and $1,365 at September 30, 2023 and December 31, 2022, respectively	106,158
Inventories, net	211,372
Prepaid expenses and other current assets	30,147
Total current assets	978,456
Noncurrent assets:
Property, plant and equipment, net	201,618
Intangible assets, net	343,729		353,676
Goodwill	869,252
Deferred tax assets	1,546
Operating lease right of use assets	118,084
Other noncurrent assets	1,444
Total noncurrent assets	1,535,673		1,526,540
Total assets	2,514,129		2,524,658
Current liabilities:
Accounts payable	18,961
Operating lease liability	3,315
Current contingent consideration	12,589
Accrued liabilities	42,543
Convertible Senior Notes, net	285,956
Total current liabilities	363,364
Noncurrent liabilities:
Deferred tax liabilities	14,036
Noncurrent operating lease liability	130,615
Noncurrent contingent consideration	13,759
Other noncurrent liabilities	3,798		3,814
Total noncurrent liabilities	162,208		209,762
Total liabilities	525,572		613,958
Commitments and contingencies (Note 11)
Equity, Attributable to Parent [Abstract]
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding	0
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,774,706 shares at September 30, 2023 and 55,557,698 shares at December 31, 2022 issued and outstanding	558
Additional paid-in capital	1,567,233
Accumulated other comprehensive loss	(43,571)
Accumulated earnings	464,337
Total stockholders' equity	1,988,557	1,970,926	1,910,700
Total liabilities and stockholders' equity	2,514,129		2,524,658
Revenue Adjustments
Current assets:
Cash and cash equivalents	0
Marketable securities held to maturity	0
Accounts receivable, net of reserves of $1,803 and $1,365 at September 30, 2023 and December 31, 2022, respectively	0
Inventories, net	0
Prepaid expenses and other current assets	2,016
Total current assets	2,016
Noncurrent assets:
Property, plant and equipment, net	0
Intangible assets, net	0
Goodwill	0
Deferred tax assets	0
Operating lease right of use assets	0
Other noncurrent assets	0
Total noncurrent assets	0
Total assets	2,016
Current liabilities:
Accounts payable	0
Operating lease liability	0
Current contingent consideration	0
Accrued liabilities	15,575
Convertible Senior Notes, net	0
Total current liabilities	15,575
Noncurrent liabilities:
Deferred tax liabilities	667
Noncurrent operating lease liability	0
Noncurrent contingent consideration	0
Other noncurrent liabilities	0
Total noncurrent liabilities	667
Total liabilities	16,242
Commitments and contingencies (Note 11)
Equity, Attributable to Parent [Abstract]
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding	0
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,774,706 shares at September 30, 2023 and 55,557,698 shares at December 31, 2022 issued and outstanding	0
Additional paid-in capital	0
Accumulated other comprehensive loss	205
Accumulated earnings	(14,431)
Total stockholders' equity	(14,226)	(13,675)
Total liabilities and stockholders' equity	2,016
Other Adjustments
Current assets:
Cash and cash equivalents	0
Marketable securities held to maturity	0
Accounts receivable, net of reserves of $1,803 and $1,365 at September 30, 2023 and December 31, 2022, respectively	0
Inventories, net	0
Prepaid expenses and other current assets	0
Total current assets	0
Noncurrent assets:
Property, plant and equipment, net	0
Intangible assets, net	6,589		6,942
Goodwill	0
Deferred tax assets	0
Operating lease right of use assets	0
Other noncurrent assets	0
Total noncurrent assets	6,589		6,942
Total assets	6,589		6,942
Current liabilities:
Accounts payable	0
Operating lease liability	0
Current contingent consideration	0
Accrued liabilities	0
Convertible Senior Notes, net	0
Total current liabilities	0
Noncurrent liabilities:
Deferred tax liabilities	(179)
Noncurrent operating lease liability	0
Noncurrent contingent consideration	0
Other noncurrent liabilities	7,356		6,942
Total noncurrent liabilities	7,177		6,942
Total liabilities	7,177		6,942
Commitments and contingencies (Note 11)
Equity, Attributable to Parent [Abstract]
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding	0
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,774,706 shares at September 30, 2023 and 55,557,698 shares at December 31, 2022 issued and outstanding	0
Additional paid-in capital	0
Accumulated other comprehensive loss	0
Accumulated earnings	(588)
Total stockholders' equity	(588)	$ (392)
Total liabilities and stockholders' equity	$ 6,589		$ 6,942

Restatement of Previously Iss_5

Restatement of Previously Issued Financial Statements - Schedule of Restatement of Previously Issued Financial Statements - Condensed Consolidated Balance Sheets (Parenthetical) (Detail) - USD ($) $ / shares in Units, $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Accounting Changes and Error Corrections [Abstract]
Accounts receivable, reserve for doubtful accounts	$ 1,803	$ 1,365
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	55,774,706	55,557,698
Common stock, shares outstanding	55,774,706	55,557,698

Restatement of Previously Iss_6

Restatement of Previously Issued Financial Statements - Schedule of Restatement of Previously Issued Financial Statements - Condensed Consolidated Comprehensive Income (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue:
Total revenue	$ 141,192	$ 200,741	$ 465,741	$ 614,774
Costs and operating expenses:
Cost of product revenue	104,634	86,514	265,786	255,130
Research and development	10,577	10,228	32,437	32,823
Selling, general and administrative	55,582	53,643	160,954	162,592
Contingent consideration	(34,292)	(2,309)	(31,266)	(11,604)
Total costs and operating expenses	136,501	148,076	427,911	438,941
Income from operations	4,691	52,665	37,830	175,833
Other income (expenses):
Investment income	6,662	2,177	18,112	2,962
Interest expense	(408)	(329)	(1,227)	(892)
Amortization of debt issuance costs	(459)	(455)	(1,373)	(1,360)
Other income (expenses)	895	(6,591)	1,500	(10,389)
Other income (expenses), net	6,690	(5,198)	17,012	(9,679)
Income before income taxes	11,381	47,467	54,842	166,154
Income tax (benefit) provision	(5,542)	7,062	2,796	28,924
Net income	$ 16,923	$ 40,405	$ 52,046	$ 137,230
Earnings Per Share [Abstract]
Basic	$ 0.3	$ 0.73	$ 0.93	$ 2.48
Diluted (Note 13)	$ 0.3	$ 0.71	$ 0.91	$ 2.39
Weighted average common shares outstanding:
Basic	55,766	55,498	55,688	55,432
Diluted (Note 13)	56,940	57,304	56,933	57,598
Net Income (Loss)	$ 16,923	$ 40,405	$ 52,046	$ 137,230
Other comprehensive income (loss):
Foreign currency translation adjustment	(5,880)	(18,170)	(8,972)	(38,375)
Comprehensive income	11,043	22,235	43,074	98,855
Product [Member]
Revenue:
Total revenue	141,156	200,708	465,630	614,668
Royalty [Member]
Revenue:
Total revenue	36	$ 33	111	$ 106
As Previously Reported
Revenue:
Total revenue	141,192		483,021
Costs and operating expenses:
Cost of product revenue	104,634		265,786
Research and development	10,577		32,437
Selling, general and administrative	55,465		160,601
Contingent consideration	(34,292)		(31,266)
Total costs and operating expenses	136,384		427,558
Income from operations	4,808		55,463
Other income (expenses):
Investment income	6,662		18,112
Interest expense	(269)		(813)
Amortization of debt issuance costs	(459)		(1,373)
Other income (expenses)	895		1,500
Other income (expenses), net	6,829		17,426
Income before income taxes	11,637		72,889
Income tax (benefit) provision	(6,535)		5,824
Net income	$ 18,172		$ 67,065
Earnings Per Share [Abstract]
Basic	$ 0.33		$ 1.2
Diluted (Note 13)	$ 0.32		$ 1.18
Weighted average common shares outstanding:
Basic	55,766		55,688
Diluted (Note 13)	56,940		56,933
Net Income (Loss)	$ 18,172		$ 67,065
Other comprehensive income (loss):
Foreign currency translation adjustment	(6,382)		(9,177)
Comprehensive income	11,790		57,888
As Previously Reported | Product [Member]
Revenue:
Total revenue	141,156		482,910
As Previously Reported | Royalty [Member]
Revenue:
Total revenue	36		111
Revenue Adjustments
Revenue:
Total revenue	0		(17,280)
Costs and operating expenses:
Cost of product revenue	0		0
Research and development	0		0
Selling, general and administrative	0		0
Contingent consideration	0		0
Total costs and operating expenses	0		0
Income from operations	0		(17,280)
Other income (expenses):
Investment income	0		0
Interest expense	0		0
Amortization of debt issuance costs	0		0
Other income (expenses)	0		0
Other income (expenses), net	0		0
Income before income taxes	0		(17,280)
Income tax (benefit) provision	1,053		(2,849)
Net income	$ (1,053)		$ (14,431)
Earnings Per Share [Abstract]
Basic	$ (0.02)		$ (0.26)
Diluted (Note 13)	$ (0.02)		$ (0.25)
Weighted average common shares outstanding:
Basic	0		0
Diluted (Note 13)	0		0
Net Income (Loss)	$ (1,053)		$ (14,431)
Other comprehensive income (loss):
Foreign currency translation adjustment	502		205
Comprehensive income	(551)		(14,226)
Revenue Adjustments | Product [Member]
Revenue:
Total revenue	0		(17,280)
Revenue Adjustments | Royalty [Member]
Revenue:
Total revenue	0		0
Other Adjustments
Revenue:
Total revenue	0		0
Costs and operating expenses:
Cost of product revenue	0		0
Research and development	0		0
Selling, general and administrative	117		353
Contingent consideration	0		0
Total costs and operating expenses	117		353
Income from operations	(117)		(353)
Other income (expenses):
Investment income	0		0
Interest expense	(139)		(414)
Amortization of debt issuance costs	0		0
Other income (expenses)	0		0
Other income (expenses), net	(139)		(414)
Income before income taxes	(256)		(767)
Income tax (benefit) provision	(60)		(179)
Net income	$ (196)		$ (588)
Earnings Per Share [Abstract]
Basic	$ (0.01)		$ (0.01)
Diluted (Note 13)	$ 0		$ (0.02)
Weighted average common shares outstanding:
Basic	0		0
Diluted (Note 13)	0		0
Net Income (Loss)	$ (196)		$ (588)
Other comprehensive income (loss):
Foreign currency translation adjustment	0		0
Comprehensive income	(196)		(588)
Other Adjustments | Product [Member]
Revenue:
Total revenue	0		0
Other Adjustments | Royalty [Member]
Revenue:
Total revenue	$ 0		$ 0

Restatement of Previously Iss_7

Restatement of Previously Issued Financial Statements - Schedule of Restatement of Previously Issued Financial Statements - Consolidated Statements of Stockholders' Equity (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance	$ 1,956,859	$ 1,805,364	$ 1,910,700	$ 1,750,067
Net Income (Loss)	16,923	40,405	52,046	137,230
Translation adjustment	(5,880)	(18,170)	(8,972)	(38,375)
Balance	1,973,743	1,835,109	1,973,743	1,835,109
Accumulated Other Comprehensive Loss
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance	(37,486)	(37,091)	(34,394)	(16,886)
Translation adjustment	(5,880)	(18,170)	(8,972)	(38,375)
Balance	(43,366)	(55,261)	(43,366)	(55,261)
Accumulated Earnings
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance	432,395	308,138	397,272	194,060
Net Income (Loss)	16,923	40,405	52,046	137,230
Balance	449,318	$ 348,543	449,318	$ 348,543
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance	1,970,926		1,910,700
Net Income (Loss)	18,172		67,065
Translation adjustment	(6,382)		(9,177)
Balance	1,988,557		1,988,557
As Previously Reported | Accumulated Other Comprehensive Loss
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance	(37,189)		(34,394)
Translation adjustment	(6,382)		(9,177)
Balance	(43,571)		(43,571)
As Previously Reported | Accumulated Earnings
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance	446,165		397,272
Net Income (Loss)	18,172		67,065
Balance	464,337		464,337
Revenue Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance	(13,675)
Net Income (Loss)	(1,053)		(14,431)
Translation adjustment	502		205
Balance	(14,226)		(14,226)
Revenue Adjustments | Accumulated Other Comprehensive Loss
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance	(297)
Translation adjustment	502		205
Balance	205		205
Revenue Adjustments | Accumulated Earnings
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance	(13,378)
Net Income (Loss)	(1,053)		(14,431)
Balance	(14,431)		(14,431)
Other Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance	(392)
Net Income (Loss)	(196)		(588)
Translation adjustment	0		0
Balance	(588)		(588)
Other Adjustments | Accumulated Earnings
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance	(392)
Net Income (Loss)	(196)		(588)
Balance	$ (588)		$ (588)

Restatement of Previously Iss_8

Restatement of Previously Issued Financial Statements - Schedule of Restatement of Previously Issued Financial Statements - Condensed Consolidated Cash flows (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net Income (Loss)	$ 16,923	$ 40,405	$ 52,046	$ 137,230
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			51,295	36,605
Amortization of debt issuance costs			1,373
Stock-based compensation	6,373	6,154	19,110	21,054
Deferred income taxes, net			(9,268)	1,722
Contingent consideration	(34,292)	(2,309)	(31,266)	(11,604)
Non-cash interest income			(2,023)	0
Operating lease right of use asset amortization			10,203	5,672
Other			1,275	210
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable			8,315	(8,609)
Inventories			25,979	(64,308)
Prepaid expenses and other assets			(12,749)	168
Other assets			(707)	(298)
Accounts payable			(8,619)	(10,124)
Accrued expenses			(12,514)	3,043
Operating lease liabilities			(7,676)	(1,548)
Long-term liabilities			79	(372)
Total cash provided by operating activities			84,853	110,201
Cash flows from investing activities:
Acquisitions, net of cash acquired			(27,843)	0
Proceeds from maturity of marketable securities held to maturity			102,323	0
Additions to capitalized software costs			(2,736)	(2,568)
Purchases of property, plant and equipment			(25,135)	(64,390)
Purchase of intellectual property			0	(45,000)
Other investing activities			21	30
Total cash provided by (used in) investing activities			46,630	(111,928)
Cash flows from financing activities:
Proceeds from exercise of stock options			356	2,784
Payment of tax withholding obligation on vesting of restricted stock			(12,178)	(15,829)
Repayment of Convertible Senior Notes			(33)	(18)
Payment of earnout consideration			(7,298)	0
Proceeds from issuance of common stock, net			(13)	0
Total cash used in financing activities			(19,166)	(13,063)
Effect of exchange rate changes on cash and cash equivalents			(4,996)	(15,661)
Net increase (decrease) in cash and cash equivalents			107,321	(30,451)
Cash, cash equivalents and restricted cash, beginning of period			523,458	603,814
Cash and cash equivalents, end of period	630,779	$ 573,363	630,779	573,363
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases			1,129	25,705
FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 31,415 shares of common stock issued for the acquisition of FlexBiosys, Inc.			5,465	0
Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 42,621 shares of common stock issued for the Avitide, Inc. contingent consideration earnout			7,229
As Previously Reported
Cash flows from operating activities:
Net Income (Loss)	18,172		67,065
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			50,942
Amortization of debt issuance costs			1,373
Stock-based compensation			19,110
Deferred income taxes, net			(9,756)
Contingent consideration	(34,292)		(31,266)
Non-cash interest income			(2,023)
Operating lease right of use asset amortization			10,203	(22,033)
Other			861
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable			8,315
Inventories			25,979
Prepaid expenses and other assets			(10,733)
Other assets			(707)
Accounts payable			(8,619)
Accrued expenses			(28,294)
Operating lease liabilities			(7,676)	26,157
Long-term liabilities			79
Total cash provided by operating activities			84,853	110,201
Cash flows from investing activities:
Acquisitions, net of cash acquired			(27,843)
Proceeds from maturity of marketable securities held to maturity			102,323
Additions to capitalized software costs			(2,736)
Purchases of property, plant and equipment			(25,135)
Purchase of intellectual property			0
Other investing activities			21
Total cash provided by (used in) investing activities			46,630
Cash flows from financing activities:
Proceeds from exercise of stock options			356
Payment of tax withholding obligation on vesting of restricted stock			(12,178)
Repayment of Convertible Senior Notes			(33)
Payment of earnout consideration			(7,298)
Proceeds from issuance of common stock, net			(13)
Total cash used in financing activities			(19,166)
Effect of exchange rate changes on cash and cash equivalents			(4,996)
Net increase (decrease) in cash and cash equivalents			107,321
Cash, cash equivalents and restricted cash, beginning of period			523,458
Cash and cash equivalents, end of period	630,779		630,779
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases			1,129
As Previously Reported | FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 31,415 shares of common stock issued for the acquisition of FlexBiosys, Inc.			5,465
As Previously Reported | Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 42,621 shares of common stock issued for the Avitide, Inc. contingent consideration earnout			7,229
Revenue Adjustments
Cash flows from operating activities:
Net Income (Loss)	(1,053)		(14,431)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			0
Amortization of debt issuance costs			0
Stock-based compensation			0
Deferred income taxes, net			667
Contingent consideration	0		0
Non-cash interest income			0
Operating lease right of use asset amortization			0
Other			0
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable			0
Inventories			0
Prepaid expenses and other assets			(2,016)
Other assets			0
Accounts payable			0
Accrued expenses			15,780
Operating lease liabilities			0
Long-term liabilities			0
Total cash provided by operating activities			0
Cash flows from investing activities:
Acquisitions, net of cash acquired			0
Proceeds from maturity of marketable securities held to maturity			0
Additions to capitalized software costs			0
Purchases of property, plant and equipment			0
Purchase of intellectual property			0
Other investing activities			0
Total cash provided by (used in) investing activities			0
Cash flows from financing activities:
Proceeds from exercise of stock options			0
Payment of tax withholding obligation on vesting of restricted stock			0
Repayment of Convertible Senior Notes			0
Payment of earnout consideration			0
Proceeds from issuance of common stock, net			0
Total cash used in financing activities			0
Effect of exchange rate changes on cash and cash equivalents			0
Net increase (decrease) in cash and cash equivalents			0
Cash, cash equivalents and restricted cash, beginning of period			0
Cash and cash equivalents, end of period	0		0
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases			0
Revenue Adjustments | FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 31,415 shares of common stock issued for the acquisition of FlexBiosys, Inc.			0
Revenue Adjustments | Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 42,621 shares of common stock issued for the Avitide, Inc. contingent consideration earnout			0
Other Adjustments
Cash flows from operating activities:
Net Income (Loss)	(196)		(588)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			353
Amortization of debt issuance costs			0
Stock-based compensation			0
Deferred income taxes, net			(179)
Contingent consideration	0		0
Non-cash interest income			0
Operating lease right of use asset amortization			0	27,705
Other			414
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable			0
Inventories			0
Prepaid expenses and other assets			0
Other assets			0
Accounts payable			0
Accrued expenses			0
Operating lease liabilities			0	(27,705)
Long-term liabilities			0
Total cash provided by operating activities			0	$ 0
Cash flows from investing activities:
Acquisitions, net of cash acquired			0
Proceeds from maturity of marketable securities held to maturity			0
Additions to capitalized software costs			0
Purchases of property, plant and equipment			0
Purchase of intellectual property			0
Other investing activities			0
Total cash provided by (used in) investing activities			0
Cash flows from financing activities:
Proceeds from exercise of stock options			0
Payment of tax withholding obligation on vesting of restricted stock			0
Repayment of Convertible Senior Notes			0
Payment of earnout consideration			0
Proceeds from issuance of common stock, net			0
Total cash used in financing activities			0
Effect of exchange rate changes on cash and cash equivalents			0
Net increase (decrease) in cash and cash equivalents			0
Cash, cash equivalents and restricted cash, beginning of period			0
Cash and cash equivalents, end of period	$ 0		0
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases			0
Other Adjustments | FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 31,415 shares of common stock issued for the acquisition of FlexBiosys, Inc.			0
Other Adjustments | Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 42,621 shares of common stock issued for the Avitide, Inc. contingent consideration earnout			$ 0

Restatement of Previously Iss_9

Restatement of Previously Issued Financial Statements - Schedule of Restatement of Previously Issued Financial Statements - Condensed Consolidated Cash flows (Parenthetical) (Detail) - shares		9 Months Ended
	Apr. 17, 2023	Sep. 30, 2023
FlexBiosys, Inc.
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Shares of common stock issued for acquisition	31,415	31,415
Avitide, Inc.
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Shares of common stock issued for acquisition		42,621

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Company's Cash, Cash Equivalents and Marketable Securities Held to Maturity (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Cash and money market funds
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized Costs	$ 630,779	$ 523,458
Cash and cash equivalents, Estimated Fair Value	630,779	523,458
Cash and cash equivalents
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized Costs	630,779	523,458
Cash and cash equivalents, Estimated Fair Value	$ 630,779	523,458
U.S. treasury bills
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized Costs		100,299
Marketable securities, Gross Unrealized Gains		24
Marketable securities, Estimated Fair Value		100,323
Cash equivalents and marketable securities
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized Costs		623,757
Marketable securities, Gross Unrealized Gains		24
Marketable securities, Estimated Fair Value		$ 623,781

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Amortized Cost and Fair Value Held to Maturity Securities by Contractual Maturity (Detail) $ in Thousands	Dec. 31, 2022 USD ($)
Fair Value Disclosures [Abstract]
Debt securities maturity within one year amortized cost	$ 100,299
Maturity of one year or less, Estimated Fair Value	$ 100,323

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Financial assets and financial liabilities measured at fair value on a recurring basis (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term contingent consideration	$ 12,589	$ 13,950
Long-term contingent consideration	13,759	51,559
Money Market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	389,473	343,929
Level 1 | Money Market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	389,473	343,929
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term contingent consideration	12,589	13,950
Long-term contingent consideration	$ 13,759	$ 51,559

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($) $ in Millions		3 Months Ended	9 Months Ended
	Apr. 17, 2023	Dec. 31, 2022	Sep. 30, 2023
Summary Of Significant Accounting Policies [Line Items]
Purchase of treasury stock		$ 100
Avitide, Inc.
Summary Of Significant Accounting Policies [Line Items]
Business combination contingent consideration			$ 125
FlexBiosys, Inc.
Summary Of Significant Accounting Policies [Line Items]
Business combination contingent consideration	$ 6.6		$ 42

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Reconciliation of the Change in the Fair Value of Contingent Consideration - Earnout (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Payment of contingent consideration earnout	$ (34,292)	$ (2,309)	$ (31,266)	$ (11,604)
Contingent Consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of December 31, 2022			65,509
Acquisition date fair value of contingent consideration earnout			6,632
Payment of contingent consideration earnout			(14,527)
Decrease in fair value of contingent consideration earnouts			(31,266)
Balance as of September 30 , 2023	$ 26,348		$ 26,348

Fair Value Measurements - Sch_4

Fair Value Measurements - Schedule of Contingent Consideration Earnout Expect to be Required to Settle Include Significant Unobservable Inputs (Detail) - Contingent Consideration - USD ($) $ in Thousands		Sep. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 26,348	$ 65,509
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 1,460
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring | Earnout Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	6.50%
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring | Volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	21.70%
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring | Revenue & Volume Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	8.20%
Manufacturing line expansions | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Probability of success		100%
Manufacturing line expansions | Monte Carlo Simulation | Fair Value, Recurring | Probability of Success
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	100%
Manufacturing line expansions | Probability-Weighted Present Value [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 5,505
Manufacturing line expansions | Probability-Weighted Present Value [Member] | Fair Value, Recurring | Earnout Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	6.30%
Minimum | Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		6.10%
Volatility		13.10%
Revenue and volume discount rate		5.10%
Minimum | Manufacturing line expansions | Probability-Weighted Present Value [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		6.10%
Maximum | Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		7.10%
Volatility		24.60%
Revenue and volume discount rate		9.30%
Maximum | Manufacturing line expansions | Probability-Weighted Present Value [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		6.40%
Avitide and FlexBiosys | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 19,383
Probability of success		100%
Avitide and FlexBiosys | Monte Carlo Simulation | Fair Value, Recurring | Probability of Success
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	100%
Avitide and FlexBiosys | Monte Carlo Simulation | Fair Value, Recurring | Earnout Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	7.10%
Avitide and FlexBiosys | Minimum | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		7.10%
[1] Unobservable inputs were weighted by the relative fair value of the contingent consideration liability.

Acquisition of FlexBiosys, In_2

Acquisition of FlexBiosys, Inc - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended	9 Months Ended
	Apr. 17, 2023	Sep. 30, 2023	Sep. 30, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Goodwill		$ 869,252	$ 869,252	$ 855,513
FlexBiosys
Business Acquisition [Line Items]
Business combination date of acquistion	Apr. 17, 2023
Equity consideration	$ 41,000
Cash consideration	29,000
Business Combination, Indemnification Assets, Range of Outcomes, Value, High	$ 6,300
Shares of common stock issued for acquisition	31,415		31,415
Value of common stock issued	$ 41,000
Business combination contingent consideration	6,600		$ 42,000
Net liabilities assumed	14,100
Business combination, intangible assets	12,600
Intangible Asset Residual Value	14,300
Business combination, acquisition related costs		500
Transaction costs		900	900
Goodwill		$ 14,321	$ 14,321
FlexBiosys | Common Stock
Business Acquisition [Line Items]
Equity consideration	5,400
Value of common stock issued	$ 5,400

Acquisition of FlexBiosys, In_3

Acquisition of FlexBiosys, Inc - Fair Value of Net Assets Acquired (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Apr. 17, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Goodwill	$ 869,252		$ 855,513
FlexBiosys
Business Acquisition [Line Items]
Cash and cash equivalents	1,090
Accounts receivable	683
Inventory	667
Prepaid expenses and other current assets	35
Property and equipment	12,034
Operating lease right of use asset	3,537
Business combination, intangible assets		$ 12,600
Goodwill	14,321
Other long-term assets	10
Accounts payable	(136)
Accrued liabilities	(314)
Operating lease liability	(39)
Operating lease liability, long-term	(3,498)
Fair value of net assets acquired	41,030
FlexBiosys | Customer relationships
Business Acquisition [Line Items]
Business combination, intangible assets	2,530
FlexBiosys | Developed technology
Business Acquisition [Line Items]
Business combination, intangible assets	9,860
FlexBiosys | Trademark and tradename
Business Acquisition [Line Items]
Business combination, intangible assets	30
FlexBiosys | Non-compete agreements
Business Acquisition [Line Items]
Business combination, intangible assets	$ 220

Acquisitionsof FlexBiosys, Inc

Acquisitionsof FlexBiosys, Inc - Estimated Useful Life and Fair Value (Detail) - FlexBiosys $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Business Acquisition [Line Items]
Fair Value	$ 12,640
Customer relationships
Business Acquisition [Line Items]
Weighted Average Useful Life (in years)	12 years
Fair Value	$ 2,530
Developed technology
Business Acquisition [Line Items]
Weighted Average Useful Life (in years)	16 years
Fair Value	$ 9,860
Trademark and tradename
Business Acquisition [Line Items]
Weighted Average Useful Life (in years)	4 years
Fair Value	$ 30
Non-compete agreements
Business Acquisition [Line Items]
Weighted Average Useful Life (in years)	5 years
Fair Value	$ 220

Restructuring Plan - Additional

Restructuring Plan - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Jul. 31, 2023	Sep. 30, 2023	Sep. 30, 2023
Restructuring Cost and Reserve [Line Items]
Non-cash inventory write-off	$ 21,000
Restructuring charges			$ 26,000
Restructuring Costs		$ 24,012	$ 24,012

Restructuring Plan - Summary of

Restructuring Plan - Summary of Restructuring Activities by Type of Cost (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ 24,012	$ 24,012
Severance & employee-related costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	2,830	2,830
Inventory Write-Off
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	17,185	17,185
Accelerated depreciation
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	3,816	3,816
Facility and Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	181	181
Cost of product revenue
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	22,711	22,711
Cost of product revenue | Severance & employee-related costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,654	1,654
Cost of product revenue | Inventory Write-Off
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	17,185	17,185
Cost of product revenue | Accelerated depreciation
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	3,788	3,788
Cost of product revenue | Facility and Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	84	84
Research and development
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	35	35
Research and development | Severance & employee-related costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	34	34
Research and development | Inventory Write-Off
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	0	0
Research and development | Accelerated depreciation
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1	1
Research and development | Facility and Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	0	0
Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,266	1,266
Selling, general and administrative | Severance & employee-related costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,142	1,142
Selling, general and administrative | Inventory Write-Off
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	0	0
Selling, general and administrative | Accelerated depreciation
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	27	27
Selling, general and administrative | Facility and Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ 97	$ 97

Restructuring Plan - Summary _2

Restructuring Plan - Summary of Activity Related to Restructuring Plan (Detail) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2023 USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ 24,012	$ 24,012
Amounts Paid		(2,649)
Non-Cash Restructuring Items		(21,225)
Restructuring Liability	138	138
Severance & employee-related costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	2,830	2,830
Amounts Paid		(2,478)
Non-Cash Restructuring Items		(214)
Restructuring Liability	138	138
Inventory Write-Off
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	17,185	17,185
Amounts Paid		0
Non-Cash Restructuring Items		(17,185)
Restructuring Liability	0	0
Accelerated depreciation
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	3,816	3,816
Amounts Paid		0
Non-Cash Restructuring Items		(3,816)
Restructuring Liability	0	0
Facility exit and other exit costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		181
Amounts Paid		(171)
Non-Cash Restructuring Items		(10)
Restructuring Liability	$ 0	$ 0

Revenue Recognition - Summary o

Revenue Recognition - Summary of Disaggregation of Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Total revenue	$ 141,192	$ 200,741	$ 465,741	$ 614,774
Product Revenue
Disaggregation of Revenue [Line Items]
Total revenue	141,156	200,708	465,630	614,668
Royalty and Other Income
Disaggregation of Revenue [Line Items]
Total revenue	$ 36	$ 33	$ 111	$ 106

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Receivables and Deferred Revenue from Contracts with Customers (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Balances from contracts with customers only:
Accounts receivable	$ 106,158	$ 116,247
Deferred revenue (included in accrued liabilities and other noncurrent liabilities in the condensed consolidated balance sheets)	28,522	19,631
Revenue recognized during periods presented relating to:
The beginning deferred revenue balance	$ 16,999	$ 13,390

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Changes in Carrying Value of Goodwill (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Goodwill [Line Items]
Balance	$ 855,513
Cumulative translation adjustment	(582)
Balance	869,252
FlexBiosys
Goodwill [Line Items]
Acquisition of FlexBiosys, Inc	14,355
Measurement period adjustment - FlexBiosys	(34)
Balance	$ 14,321

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Finite-Lived Intangible Liabilities [Line Items]
Impairment of intangible assets			$ 0
Amortization of Intangible Assets	$ 7.6	$ 6.6	$ 22.8	$ 19.8

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Intangible Assets [Line Items]
Gross Carrying Value	$ 473,218	$ 461,072
Gross Carrying Value	473,918	461,772
Accumulated Amortization	(123,600)	(101,154)
Accumulated Amortization	(123,600)	(101,154)
Net Carrying Value	349,618	359,918
Net Carrying Value	$ 350,318	$ 360,618
Weighted Average Useful Life (in years)	16 years	16 years
Trademark
Intangible Assets [Line Items]
Gross Carrying Value	$ 700	$ 700
Net Carrying Value	700	700
Technology - developed
Intangible Assets [Line Items]
Gross Carrying Value	207,130	197,405
Accumulated Amortization	(40,446)	(30,992)
Net Carrying Value	$ 166,684	$ 166,413
Weighted Average Useful Life (in years)	16 years	16 years
Patents
Intangible Assets [Line Items]
Gross Carrying Value	$ 240	$ 240
Accumulated Amortization	(240)	(240)
Net Carrying Value	$ 0	$ 0
Weighted Average Useful Life (in years)	8 years	8 years
Customer relationships
Intangible Assets [Line Items]
Gross Carrying Value	$ 255,113	$ 252,934
Accumulated Amortization	(78,929)	(66,559)
Net Carrying Value	$ 176,184	$ 186,375
Weighted Average Useful Life (in years)	15 years	15 years
Trademarks
Intangible Assets [Line Items]
Gross Carrying Value	$ 7,709	$ 7,682
Accumulated Amortization	(1,653)	(1,319)
Net Carrying Value	$ 6,056	$ 6,363
Weighted Average Useful Life (in years)	19 years	19 years
Other intangibles
Intangible Assets [Line Items]
Gross Carrying Value	$ 3,026	$ 2,811
Accumulated Amortization	(2,332)	(2,044)
Net Carrying Value	$ 694	$ 767
Weighted Average Useful Life (in years)	4 years	4 years

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Amortization Expense for Amortized Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Finite-Lived Intangible Liabilities [Line Items]
2023 (remaining three months)	$ 7,622
2024	30,029
2025	29,691
2026	29,663
2027	29,630
2028 and thereafter	222,983
Total	$ 349,618	$ 359,918

Consolidated Balance Sheet De_3

Consolidated Balance Sheet Detail - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventory [Line Items]
Raw materials	$ 128,894	$ 149,438
Work-in-process	5,630	6,183
Finished products	76,848	82,656
Total inventories, net	$ 211,372	$ 238,277

Consolidated Balance Sheet De_4

Consolidated Balance Sheet Detail - Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Land	$ 950	$ 1,003
Buildings	1,637	1,599
Leasehold improvements	124,925	115,672
Equipment	111,625	94,613
Furniture, fixtures and office equipment	8,786	8,307
Computer hardware and software	35,359	29,813
Construction in progress	37,679	31,553
Other	410	420
Total property, plant and equipment	321,371	282,980
Less - Accumulated depreciation	(119,753)	(92,307)
Total property, plant and equipment, net	$ 201,618	$ 190,673

Consolidated Balance Sheet De_5

Consolidated Balance Sheet Detail - Schedule of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Schedule of Accrued Liabilities [Line Items]
Employee compensation	$ 13,727	$ 33,522
Deferred revenue	27,954	19,283
Income taxes payable	946	2,459
Other	15,491	15,856
Total accrued liabilities	$ 58,118	$ 71,120

Convertible Senior Notes - Addi

Convertible Senior Notes - Additional Information (Detail) - 0.375% Convertible Senior Notes due 2024 $ in Millions		9 Months Ended
	Jul. 19, 2019 USD ($)	Sep. 30, 2023 USD ($) Days	Dec. 31, 2022 USD ($)	Jul. 31, 2019 USD ($)
Debt Instrument [Line Items]
Notes issued	$ 287.5			$ 287.5
Notes, interest rate	0.375%
Proceeds from issuance of convertible senior notes, net of costs	$ 278.5
Interest repayment terms		Interest is payable semi-annually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020.
Notes, due date		Jul. 15, 2024
Notes, carrying value		$ 286	$ 284.6
Fair value of the note		405.3	$ 452
Additional Notes issued	$ 37.5
Debt instrument amount convertible into equity		$ 0.1
Debt Instrument, Convertible, Threshold Trading Days | Days		20
Debt Instrument, Convertible, Threshold Consecutive Trading Days | Days		30
Notes threshold percentage of stock price trigger		130%

Convertible Senior Notes - Conv

Convertible Senior Notes - Convertible Debt (Detail) - 0.375% Convertible Senior Notes due 2024 - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Principal amount	$ 287,437	$ 287,470
Unamortized debt issuance costs	(1,481)	(2,855)
Total covertible senior notes	$ 285,956	$ 284,615

Convertible Senior Notes - Sche

Convertible Senior Notes - Schedule of convertiable note interest expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Debt Instrument [Line Items]
Amortization of debt issuance costs			$ 1,373	$ 1,360
2019 Notes
Debt Instrument [Line Items]
Contractual interest expense	$ 269	$ 270	808	809
Amortization of debt issuance costs	459	455	1,373	1,360
Total	$ 728	$ 725	$ 2,181	$ 2,169
Debt Instrument, Interest Rate, Effective Percentage	1%	1%	1%	1%

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	May 31, 2023	Dec. 31, 2022	Dec. 31, 2018
Stockholders Equity Note Disclosure [Line Items]
Aggregate intrinsic value of stock options exercised	$ 3.4	$ 9.8
Weighted average grant date fair value of share-based awards granted	$ 85.7	$ 76.64
Weighted average grant date fair value of restricted stock units granted	$ 174.86
Total unrecognized compensation cost	$ 66
Unrecognized compensation cost, weighted average remaining requisite service period	2 years 10 months 17 days
Number of unvested options and restricted stock units	2,156,681
Common stock, shares issued	55,774,706			55,557,698
Avitide
Stockholders Equity Note Disclosure [Line Items]
Common stock, shares issued			42,621
Earnout consideration earned			50%
2018 Plan
Stockholders Equity Note Disclosure [Line Items]
Common stock shares reserved for Issuance					2,778,000
Incentive options, vesting period	1,704,118
Unvested Options
Stockholders Equity Note Disclosure [Line Items]
Incentive options, vesting period	5 years
Restricted Stock Units and Performance Stock Units
Stockholders Equity Note Disclosure [Line Items]
Aggregate intrinsic value of restricted stock units vested	$ 32.3	$ 40.4
Weighted average grant date fair value of restricted stock units granted	$ 174.86	$ 191.55
Restricted Stock Unit
Stockholders Equity Note Disclosure [Line Items]
Closing price of common stock	$ 159.01

Stockholders' Equity - Stock-Ba

Stockholders' Equity - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 6,373	$ 6,154	$ 19,110	$ 21,054
Cost of product revenue
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	393	610	1,506	1,847
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	700	534	2,095	1,955
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 5,280	$ 5,010	$ 15,509	$ 17,252

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Option Activity (Detail) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares
Options Outstanding
Options outstanding at December 31, 2022 | shares | shares	609,965
Granted | shares | shares	66,069
Exercised | shares | shares	(22,872)
Forfeited/expired/cancelled | shares	(2,000)
Options outstanding at September 30, 2023 | shares | shares	651,162
Options exercisable at September 30, 2023 | shares | shares	371,782
Vested and expected to vest at September 30, 2023 (1) | shares | shares	637,673	[1]
Weighted-Average Exercise Price Per Share
Options outstanding at December 31, 2022 | $ / shares	$ 71.74
Granted | $ / shares	173.08
Exercised | $ / shares	15.52
Forfeited/expired/cancelled | $ / shares	199.71
Options outstanding at September 30, 2023 | $ / shares	83.6
Options exercisable at September 30, 2023 | $ / shares	61.46
Vested and expected to vest at September 30, 2023 | $ / shares	$ 83.18	[1]
Weighted-Average Remaining Contractual Term (in years)
Vested and expected to vest at September 30, 2023	5 years 8 months 23 days	[1]
Aggregate Intrinsic Value
Vested and expected to vest at September 30, 2023 | $	$ 53,173	[1]
[1] Represents the number of vested options as of September 30, 2023 plus the number of unvested options expected to vest as of September 30, 2023 based on the unvested outstanding options at September 30, 2023 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Option Activity (Parenthetical) (Detail) - Employee Stock Option	Sep. 30, 2023
Awards Granted to Non-Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	8%
Awards Granted to Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	3%

Stockholders' Equity - Summar_3

Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Options Outstanding
Unvested at December 31, 2022 | shares	531,034
Awarded | shares	175,475
Vested | shares	(173,714)
Forfeited/cancelled | shares	(53,920)
Unvested at September 30, 2023 | shares	478,875
Vested and expected to vest at September 30, 2023 | shares	411,646	[1]
Weighted Average Grant Date Fair Value
Weighted Average, Unvested at December 31,2022 | $ / shares	$ 142.57
Weighted Average, Awarded | $ / shares	174.86
Weighted Average, Vested | $ / shares	118.7
Weighted Average, Forfeited/Cancelled | $ / shares	179.53
Weighted Average, Unvested at September 30, 2023 | $ / shares	188.41
Weighted Average, Vested and expected to vest at September 30, 2023 | $ / shares	$ 153.79	[1]
[1] Represents the number of vested stock units as of September 30, 2023 plus the number of unvested stock units expected to vest as of September 30, 2023 based on the unvested outstanding stock units at September 30, 2023 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.

Stockholders' Equity - Summar_4

Stockholders' Equity - Summary of Restricted Stock Unit Activity (Parenthetical) (Detail) - Restricted Stock Units and Performance Stock Units	Sep. 30, 2023
Awards Granted to Non-Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	8%
Awards Granted to Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	3%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
NGL Impact A [Member] | Research and Development Arrangement [Member]
Commitments and Contingencies [Line Items]
Royalty payments	$ 0.8	$ 0.4	$ 3.1	$ 1.5

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Aug. 16, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Taxes [Line Items]
Income tax (benefit) provision		$ (5,542)	$ 7,062	$ 2,796	$ 28,924
Effective tax rate		(48.70%)	14.90%	5.10%	17.40%
Inflation Reduction Act Of Two Thousand Twenty Two [Member]
Income Taxes [Line Items]
Percentage of alternative minimum tax	15%
Percent of excise tax on net stock repurchases	1%

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended			9 Months Ended
	Mar. 04, 2022	Sep. 30, 2023	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Jul. 31, 2019	Jul. 19, 2019
Common stock excluded from calculation of diluted earnings per share		301,404	112,179		328,179	149,187
Dilutive effect on shares of conversion premium		735,150	1,130,530		776,339	1,500,717
Denominator for diluted earnings per share - adjusted weighted average shares used in computing net income per share - diluted		56,940	57,304		56,933	57,598
Charges associated with convertible debt instruments, net of tax		$ 0	$ 0		$ 0	$ 387
AccountingStandardsUpdate202006Member
Denominator for diluted earnings per share - adjusted weighted average shares used in computing net income per share - diluted	3,474,429
Charges associated with convertible debt instruments, net of tax				$ 400
0.375% Convertible Senior Notes due 2024
Principal amount							$ 287,500	$ 287,500

Earnings Per Share - Reconcilia

Earnings Per Share - Reconciliation of Basic and Diluted Shares Amounts (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Numerator
Net income	$ 16,923	$ 40,405	$ 52,046	$ 137,230
Effect of dilutive securities
Charges associated with convertible debt instruments, net of tax	0	0	0	387
Numerator for diluted earnings per share - net income available to common stockholders after the effect of dilutive securities	$ 16,923	$ 40,405	$ 52,046	$ 137,617
Denominator
Weighted average shares used in computing net income per share - basic	55,766	55,498	55,688	55,432
Effect of dilutive shares
Options and stock units	439	673	469	663
Convertible Senior Notes	735	1,131	776	1,501
Dilutive effect of unvested performance stock units	0	2	0	2
Dilutive potential common shares	1,174	1,806	1,245	2,166
Denominator for diluted earnings per share - adjusted weighted average shares used in computing net income per share - diluted	56,940	57,304	56,933	57,598
Earnings per share:
Basic	$ 0.3	$ 0.73	$ 0.93	$ 2.48
Diluted	$ 0.3	$ 0.71	$ 0.91	$ 2.39

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Principal Owner - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Related Party Transaction [Line Items]
Rental expense	$ 0.1	$ 0.2	$ 0.5	$ 0.5
Minimum | Spectrum Inc.
Related Party Transaction [Line Items]
Non controlling ownership interest minimum	5%		5%

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) Segment	Sep. 30, 2022 USD ($)	Dec. 31, 2022
Number of operating segments | Segment			1
Accounts receivable, percentage by customer	100%	100%	100%	100%
Revenue	$ 141,192	$ 200,741	$ 465,741	$ 614,774
Sales Revenue
Revenue	$ 0	$ 0	$ 0	$ 0
Customer Concentration Risk | Accounts Receivable [Member] | Purolite [Member]
Accounts receivable, percentage by customer					12.70%
Customer Concentration Risk | Accounts Receivable [Member] | Customer Number One [Member]
Accounts receivable, percentage by customer			10%
Customer Concentration Risk | Total Trade Accounts Receivable Royalties And Other Receivables | Purolite [Member]
Accounts receivable, percentage by customer					10%
Customer Concentration Risk | Minimum [Member] | Sales Revenue
Accounts receivable, percentage by customer	10%	10%	10%	10%

Segment Reporting - Percentage

Segment Reporting - Percentage of Revenue by Geographic Area (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Concentration Risk [Line Items]
Revenues, percentage by country	100%	100%	100%	100%
Geographic Concentration Risk | Total Revenue | North America
Concentration Risk [Line Items]
Revenues, percentage by country	49%	42%	46%	42%
Geographic Concentration Risk | Total Revenue | Europe
Concentration Risk [Line Items]
Revenues, percentage by country	34%	35%	34%	38%
Geographic Concentration Risk | Total Revenue | APAC/Other
Concentration Risk [Line Items]
Revenues, percentage by country	17%	23%	20%	20%

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) - Subsequent Event - Metenova AB $ in Millions	Oct. 02, 2023 USD ($)
Subsequent Event [Line Items]
Business combination date of acquistion	Oct. 02, 2023
Cash Acquired from Acquisition	$ 173